VOLUME 26 1987

SUBJECT INDEX

Acetylcholinesterase, 625
cholinesterase inhibitors
heptyl
locomotor activity
memory
physostigmine analogues
Acetylcholinesterase activity, 813
choline acetyltransferase activity
diisopropylphosphofluoridate
muscarinic receptors
nicotinic receptors
recovery
sex differences
Acetylcholinesterase inhibition, 119
formetanate
operant behavior
schedule-controlled responding
ACh formation, 305
DOPAC/DA ratio
dose-dependent effects
locomotor activity
neurochemical actions
nicotine
time-dependent effects
Acquisition and maintenance, 677
drinking
naloxone
schedule-induced polydipsia
Acute administration
alcohol, 29
analgesia, 153
angiotensin II, 431
antidepressants, 153
antidipsogenic effect, 431
behavioral impairment, 29
bromocriptine, 431
CGS 9896, 601
chronic administration, 153, 593, 601
clomipramine, 593
diazepam, 601
differential effects, 593
diisopropylfluorophosphate, 281
drinking, 431
drug comparisons, 601
drug interaction, 153
endogenous opioid system, 153
beta-endorphin concentrations, 153
estrogen pretreatment, 431
5-HT autoreceptors, 593
human studies, males, 29
isoproterenol, 431
learning, 29
nialamide, 593
serotonin efflux, 593
serotoninergic system, 153
subacute administration, 281
tolerance, 29, 601
tolerance development, 281
withdrawal effects, 601
Acute exposure, 533
clonidine
hypothalamus
in vitro
in vivo
testes
testosterone
Δ^9-tetrahydrocannabinol
Adaptation, 141
behavioral effects
environmental familiarity
prior drug experience
delta-9-tetrahydrocannabinol
Additive effects, 427
amino acid precursors
caffeine
catecholamine release
drug interactions
locomotor activity
nicotine
Adenylate cyclase, 693
chronic administration
ethanol
in vitro
liquid diet
tolerance
Adrenergic agonists, 757
adrenergic antagonists
chickens
dose-response relationship
epinephrine
food intake
hepatic portal vein
vagotomy
beta-Adrenergic agonists, 11
β1 receptors
β2 receptors
betaxolol
chronic administration
clenbuterol
IPS-339
spontaneous motor activity
Adrenergic antagonists, 757
adrenergic agonists
chickens
dose-response relationship
epinephrine
food intake
hepatic portal vein
vagotomy
α_1-Adrenergic properties, 265
B-HT920
dopaminergic properties
morphine-withdrawal behavior
α-Adrenoceptors, 791
clonidine
iminodipropionitrile
prazosin
spasmodic syndrome, drug induced
α_2-Adrenoceptors
β-adrenoceptors, 259
chronic administration, 259
clonidine, 437
immobilization stress, 259
jaw opening reflex, 437
muscarinic cholinoceptors, 259
nicotine, 259
nociception, 437
rabbit/rat comparisons, 437
stress, repeated, 259
β-Adrenoceptors, 259
α_2-adrenoceptors
chronic administration
immobilization stress
muscarinic cholinoceptors
nicotine
stress, repeated
Adrenocorticotropic hormone
apomorphine, 503
hypophysectomy, 277, 503
monosodium glutamate, 503
penile erection, 277, 503
yawning, 277, 503
Age differences
aggression, shock-induced, 83
antidepressants, 313
co-dergocrine, 95
GABA levels, brain, 83
inbred mice, 83
kinetics, 313
learning and memory, 95
local cerebral glucose utilization, 95
locus ceruleus, 95
maze performance, 95
memory, short-term, 313
strain differences, 83
Aggression, 229
brain transmitters
dose related effects
footshock aggression
propranolol
Aggression, drug induced, 217
amygdala
locomotor activity
norepinephrine
Aggression, shocked-induced, 83
age differences
GABA levels, brain
inbred mice
strain differences
Alcohol
acute administration, 29
alcohol preference, 749
behavioral impairment, 29
β-carbolines, 749
drug comparisons, 749
harmalan, 749
human studies, males, 29
learning, 29
tolerance, 29
ultradian rhythm, 749
Alcohol nonpreferring rats, 389
alcohol preferring rats
forebrain
monoamine content
strain differences
Alcohol preference, 749
alcohol
β-carbolines
drug comparisons
harmalan
ultradian rhythm
Alcohol preferring rats, 389
alcohol nonpreferring rats
forebrain
monoamine content
strain differences
Alkali metals, 235
in vitro

in vivo
lithium
mechanism of action
superoxide dismutase
Amfonelic acid, 413
dopamine agonists
drug discrimination
Amino acid precursors, 427
additive effects
caffeine
catecholamine release
drug interactions
locomotor activity
nicotine
Amphetamine, 167
drug interaction
fixed-interval schedule
fixed-ratio schedule
naloxone
d-Amphetamine
brain monoamines, 821
chlordiazepoxide, 577
directional behavior, 527
dopamine, 821
dose differences, 821
footshock, 17
habituation, 7
intruder treatment, 577
locomotor activity, nocturnal, 821
long-lasting effects, 821
maternal aggression, 577
maternal treatment, 577
opponent size, 577
perseveration, 527
rearing, off-wall, 7
rearing, on-wall, 7
rotational behavior, 17, 527
rotational bias, 17
serotonin, 821
sex differences, 17
spontaneous alternation, 527
stereotyped behavior, 821
Amygdala
aggression, drug induced, 217
convulsions, drug induced, 159
kindling, 159
locomotor activity, 217
norepinephrine, 217
olfactory bulb, 159
pentylenetetrazol, 159
seizures, 159
sensitization, 159
Analgesia
acute administration, 153
antidepressants, 153
chronic administration, 153
corticotropin-releasing hormone, 699
drug interaction, 153
endogenous opioid system, 153
beta-endorphin concentrations, 153
GABA agonists, 463
GABA-transaminase inhibitors, 463
locomotor activity, 539
morphine, 539
noradrenergic pathways, 463
novelty-induced behavior, 699
post-weaning exposure, 539
pre-weaning exposure, 539
serotoninergic system, 153
Analgesic effect, 57
β-endorphin
oxytocin
tolerance
Angiotensin II, 431
acute administration
antidipsogenic effect
bromocriptine
drinking
estrogen pretreatment
isoproterenol
Anorexia, 5-HT induced, 333
eating
5-hydroxytryptamine
ritanserin
Antidepressants
acute administration, 153
age differences, 313
analgesia, 153
benzodiazepine receptors, 35
catecholamines, 351
chronic administration, 153
DOPAC, 351
dopamine, 351
drug comparisons, 351
drug interaction, 153
endogenous opioid system, 153
beta-endorphin concentrations, 153
[^{3}H]flunitrazepam binding sites, 35
kinetics, 313
lesions, nucleus accumbens, 351
memory, short-term, 313
muricide, 351
nucleus accumbens, 351
route of administration, 35
serotoninergic system, 153
Antidipsogenic effect, 431
acute administration
angiotensin II
bromocriptine
drinking
estrogen pretreatment
isoproterenol
Anti-immobility effect, 417
chronic administration
desipramine
perinatal undernutrition
Antinociception
continuous infusion, 131
cross tolerance, 131
lesions, electrolytic, 187
muscimol, 187
self-injurious behavior, 187
spinal cord, 131
stereotyped behavior, 187
substantia nigra, 187
superior colliculus, 187
ventromedial thalamus, 187
Anxiolytic drugs, 111
corridor-type runway
drug screening
Apomorphine
adrenocorticotropic hormone, 503
electrophysiological correlates, 299
hypophysectomy, 503
monosodium glutamate, 503
penile erection, 503
sniffing, 299
stereotyped behavior, 299
yawning, 503
Apparatus
corridor-type runway, 111
gastric fistulas, 497
holeboard, 631, 643
macroelectrodes, 299
mini-osmotic pumps, 131
radial arm maze, 1, 365
radial maze, 23
rotometer, 17
shuttlebox, 17, 509
Y-maze, 527
Appetite, 321
eating
food intake
human studies, females
phenylpropanolamine
Anterior hypothalamus/preoptic area, 373
cats
hypothermia
α-noradrenergic receptors
thermoregulation
Atropine, 475
BM123
drug interaction
muscarinic receptor
N-methyl atropine
reversible association
Atropine sulfate, 619
cyclic AMP
footshock
immobilization
methylatropine nitrate
pituitary
prolactin
stress
Attack targets, 61
defensive behavior
ethanol
group formation
offensive behavior
social/agonistic interactions
Autoreceptor blockade, 223
dopamine receptor hypersensitivity
neuroleptics
Avoidance, 509
D1 receptors
operant responding
SCH 23390
Avoidance performance, 241
haloperidol
latent inhibition

Behavioral activation, 715
benzazepine enantiomers
dopamine agonists
drug comparisons
EEG activation
rabbits
SCH 23388
SCH 23390
Behavioral effects
adaptation, 141
caffeine, 801, 841
clonidine, 421
cola seeds, 841
diazepam, 801
dose effects, 801
drug comparisons, 841
drug interactions, 801
electrical activity, 357
environmental familiarity, 141
ethylcholine aziridinium ion, 357
hippocampus, 357, 421
human studies, males, 801
intrahippocampal administration, 421
prior drug experience, 141

psychostimulants, 841
rhythmical slow activity, 357
salbutamol, 421
sub-chronic treatment, 841
Δ^9-tetrahydrocannabinol, 141
yohimbine, 421
Behavioral impairment, 29
acute administration
alcohol
human studies, males
learning
tolerance
Behavioral-potency comparison, 425
N-methyl-1-(3,4-methylene-dioxyphenyl)-2-aminopropane
phenylisopropylamines
schedule-controlled responding
Benserazide, 407
L-threo-3,4-dihydroxyphenylserine
FLA-63
locomotor activity
nialamide
norepinephrine levels
Benzodiazepine antagonists, 631
chlordiazepoxide
drug interactions
exploration
habituation
locomotor activity
RO 15-1788
Benzazepine enantiomers, 715
behavioral activation
dopamine agonists
drug comparisons
EEG activation
rabbits
SCH 23388
SCH 23390
Benzodiazepine receptor ligands, 247
differential effects
drinking
isotonic saline consumption
rats, males
water consumption
Benzodiazepine receptors
antidepressants, 35
CGS 8216, 497
[^{3}H]flunitrazepam binding sites, 35
palatability, 497
route of administration, 35
sham feeding, 497
Benzodiazepines, 521
monkeys
self-administration
β1 receptors, 11
beta-adrenergic agonists
β2 receptors
betaxolol
chronic administration
clenbuterol
IPS-339
spontaneous motor activity
β2 receptors, 11
beta-adrenergic agonists
β1 receptors
betaxolol
chronic administration
clenbuterol
IPS-339
spontaneous motor activity
Betaxolol, 11
beta-adrenergic agonists
β1 receptors
β2 receptors
chronic administration
clenbuterol
IPS-339
spontaneous motor activity
B-HT920, 265
α_1-adrenergic properties
dopaminergic properties
morphine-withdrawal behavior
Biogenic amines, 725
lesions, midbrain raphe nucleus
lesions, nucleus accumbens
monoamine content
muricide
olfactory bulbectomy
Biphasic effects, 65
dose-response
locomotor activity
toluene inhalation
Blood glucose responses, 491
hyperglycemia, stress-induced
plasma insulin responses
sympathetic nervous system
BM123, 475
atropine
drug interaction
muscarinic receptor
N-methyl atropine
reversible association
Body weight gain, 293
gastric secretion
gastric ulceration
mast cells
stress
zinc deficiency
Brain
anterior caudate nucleus, 607
anterior globus pallidus, 49
anterior hypothalamic nucleus, 271
anterior hypothalamus/preoptic area, 373
anterior striatum, 389
amygdala, 83, 159, 217, 585
basal ganglia, 49, 661
basolateral amygdala, 351, 725
CA3 of the hippocampus, 357
caudate nucleus, 253, 271
caudate-putamen, 95
Central amygdala, 351, 725
cerebellum, 83, 693, 847
cerebral cortex, 203, 259
corpus callosum, 357
cortex, 173, 305, 613, 653, 813, 847
dorsal hippocampus, 299
dorsal raphe nucleus, 453
dorsomedial nucleus, 271
entopeduncular nucleus, 49
fimbria-fornix, 357
frontal cortex, 95, 351, 389, 725, 829
fronto-parietal cortex, 553
globus pallidus, 49, 95
habenula nucleus, 643
hindbrain, 813
hippocampus, 95, 259, 357, 365, 421, 553, 613, 635, 653, 813, 829, 847
hypothalamus, 49, 173, 271, 333, 373, 533, 585, 653, 813, 829, 847
inferotemporal cortex, 89
internal capsule, 95
lateral hypothalamus, 351, 725, 771
locus ceruleus, 95, 453
mamillary body, 725
medial amygdala, 725
medial forebrain bundle, 731
medial frontal cortex, 821
median eminence, 533
median raphe nucleus, 95
medulla, 647
midbrain, 173, 613, 813
neocortex, 299, 357
nucleus accumbens, 49, 351, 389, 585, 607, 765, 821
olfactory bulb, 159, 299
parahippocampal cortex, 365
paraventricular nucleus, 271, 333
perifornical lateral hypothalamus, 271
pituitary, 533, 619
pons-medulla, 173
prefrontal cortex, 89
Purkinje neurons, 453
pyriform cortex, 585, 607
raphe nuclei, 83
rostral caudate putamen, 351
striatum, 49, 83, 173, 305, 357, 365, 613, 635, 693, 813, 821, 829, 847
subiculum, 95
substantia nigra, 83, 187
subthalamic nucleus, 49
superior colliculus, 187
thalamic ventromedial nucleus, 49
ventral globus pallidus, 49
ventral tegmental area, 453
ventromedial hypothalamus, 725
ventromedial thalamus, 49, 187
zona compacta, 453
Brain catecholamines, 613
catecholamine turnover
dopamine
norepinephrine
pregnancy
seizure susceptibility
Brain monoamines, 821
d-amphetamine
dopamine dose differences
locomotor activity, nocturnal
long-lasting effects
serotonin
stereotyped behavior
Brain plasticity, experience dependent, 341
difluoromethylornithine
environmental complexity
environmental impoverishment
polyamines
Brain transmitters, 229
aggression
dose related effects
footshock aggression
propranolol
Bromocriptine, 431
acute administration
angiotensin II
antidipsogenic effect
drinking
estrogen pretreatment
isoproterenol

Caffeine
additive effects, 427
amino acid precursors, 427
behavioral effects, 801, 841
catecholamine release, 427

cola seeds, 841
diazepam, 801
dose effects, 801
drug comparisons, 841
drug interactions, 427, 801
human studies, males, 801
inbred strains, 381
locomotor activity, 427
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, 381
nicotine, 427
picrotoxinin, 381
psychostimulants, 841
Ro 5-4864, 381
seizure susceptibility, 381
sub-chronic treatment, 841
β-Carbolines, 749
alcohol
alcohol preference
drug comparisons
harmalan
ultradian rhythm
Castration, 781
conditioned place preference
estrous
mating behavior
naloxone
sexual reward
Catalepsy, 45
locomotor activity, backward walking
morphine
RU 24213
SKF 38393
Cataleptic behavior, 543
cholinergic system
dopaminergic system
prostaglandin D_2
serotonergic system
Catecholamine concentrations, 851
experimental allergic encephalomyelitis
spleen
Catecholamine levels, 271
catecholamine turnover
food deprivation
hypothalamus
α-methyl-p-tyrosine
Catecholamine release, 427
additive effects
amino acid precursors
caffeine
drug interactions
locomotor activity
nicotine
Catecholamine turnover
brain catecholamines, 613
catecholamine levels, 271
dopamine, 613
food deprivation, 271
hypothalamus, 271
α-methyl-p-tyrosine, 271
norepinephrine, 613
pregnancy, 613
seizure susceptibility, 613
Catecholamines, 351
antidepressants
DOPAC
dopamine
drug comparisons
lesions, nucleus accumbens
muricide
nucleus accumbens
Catecholaminergic agonists, 731
catecholaminergic antagonists
drug comparisons
electrical brain stimulation
quantitative determination
rewarding efficacy
Catecholaminergic antagonists, 731
catecholaminergic agonists
drug comparisons
electrical brain stimulation
quantitative determination
rewarding efficacy
Cats
anterior hypothalamus/preoptic area, 373
defecation, 639
flurazepam, 647
hypothermia, 373
α-noradrenergic receptors, 373
pentobarbital, 647
respiration, 647
respiratory neurons, 647
thermoregulation, 373
thyrotropin-releasing-hormone, 639
Caudate nucleus, 253
dopamine receptors
rabbit/rat comparisons
^{3}H-spiperone
^{3}H-spiperone binding
CGS 8216
benzodiazepine receptors, 497
chlordiazepoxide, 709
differential effects, 145
direct enhancement, 709
drinking, 145
drug interactions, 709
eating, 145
food deprivation, 145
naltrexone, 145
palatability, 497
positive palatability, 709
Ro 15-1788, 709
sham feeding, 497
water deprivation, 145
CGS 9896, 601
acute administration
chronic administration
diazepam
drug comparisons
tolerance
withdrawal effects
Chickens, 757
adrenergic agonists
adrenergic antagonists
dose-response relationship
epinephrine
food intake
hepatic portal vein
vagotomy
Chlordiazepoxide
d-amphetamine, 577
benzodiazepine antagonists, 631
CGS 8216, 709
direct enhancement, 709
drug interactions, 631, 709
exploration, 631
habituation, 631
intruder treatment, 577
locomotor activity, 631
maternal aggression, 577
maternal treatment, 577
opponent size, 577
positive palatability, 709
restraint stress, 561
Ro 15-1788, 631, 709
stress tolerance, 561
ulcers, 561
Chlorimipramine, 207
desipramine
hole board response
stress
stress-induced behavior
voluntary drug ingestion
Choline acetyltransferase (ChAT) activity, 813
acetylcholinesterase activity
diisopropylphosphofluoridate
muscarinic receptors
nicotinic receptors
recovery
sex differences
Choline uptake, 365
memory, reference
memory, working
N-ethyl-acetylcholine aziridinium
Cholinergic activity, 553
hippocampus
odor aversions
taste aversions
Cholinergic system, 543
cataleptic behavior
dopaminergic system
prostaglandin D_2
serotonergic system
Cholinergic stimulation, 771
drinking
lateral hypothalamus
M_1 muscarinic receptors
M_2 muscarinic receptors
Cholinesterase inhibition, 625
acetylcholinesterase
heptyl
locomotor activity
memory
physostigmine analogues
Chronic administration
acute administration, 153, 593, 601
adenylate cyclase, 693
beta-adenergic agonists, 11
α_2-adrenoceptors, 259
β-adrenoceptors, 259
analgesia, 153
antidepressants, 153
anti-immobility effect, 417
β1 receptors, 11
β2 receptors, 11
betaxolol, 11
CGS 9896, 601
clenbuterol, 11
clomipramine, 593
cognitive effects, 1
[^{3}H]DADLE binding, 203
desipramine, 417
diazepam, 601
differential effects, 593
dopamine receptor binding, 635
down-regulation, 635
drug comparisons, 601
drug interaction, 153
electroconvulsive shock treatment, 203
endogenous opioid system, 153
beta-endorphin concentrations, 153
ethanol, 693
fluphenazine, 635

haloperidol, 1
5-HT autoreceptors, 593
6-hydroxydopamine, 203
imipramine, 203
immobilization stress, 259
in vitro, 693
IPS-339, 11
liquid diet, 693
lithium, 635
monkeys, 191
motor effects, 1
muscarinic cholinoceptors, 259
muscarinic receptor binding, 635
naloxone, 191
nialamide, 593
nicotine, 259
opioid δ receptor, 203
oral movements, 1
perinatal undernutrition, 417
rate of responding, 191
reserpine, 203
serotonin efflux, 593
serotoninergic system, 153
shock titration, 191
spontaneous motor activity, 11
stress, repeated, 259
tolerance, 601, 693
withdrawal effects, 601
Chronic treatment, 287
depression, drug induced
reserpine
5-HT receptors
5-hydroxytryptophan
Circannual rhythm, 565
hibernation
seasonal difference
squirrels
thermoregulation
Clenbuterol, 11
beta-adrenergic agonists
β1 receptors
β2 receptors
betaxolol
chronic administration
IPS-339
spontaneous motor activity
Clomipramine, 593
acute administration
chronic administration
differential effects
5-HT autoreceptors
nialamide
serotonin efflux
Clonidine
acute exposure, 533
alpha-adrenoceptors, 437, 791
behavioral effects, 421
hippocampus, 421
hypothalamus, 533
iminodipropionitrile, 791
intrahippocampal administration, 421
in vitro, 533
in vivo, 533
jaw opening reflex, 437
nociception, 437
prazosin, 791
rabbit/rat comparisons, 437
salbutamol, 421
spasmodic syndrome, drug-induced, 791
testes, 533
testosterone, 533
Δ9-tetrahydrocannabinol, 533
yohimbine, 421
Cocaine
drug comparisons, 573
estrous cycle, 37
haloperidol, 37
in vivo, 453
locomotor activity, 573
monoaminergic neurotransmission, 453
neuroleptic activity, 37
norcocaine, 573
ovariectomy, 37
route of administration, 573
self-administration, 37
Co-dergocrine, 95
age differences
learning and memory
local cerebral glucose utilization
locus ceruleus
maze performance
Cognitive effects, 1
chronic administration
haloperidol
motor effects
oral movements
Cola seeds, 841
behavioral effects
caffeine
drug comparisons
psychostimulants
sub-chronic treatment
Concentration variations, 653
footshock
norepinephrine
stress, chronic
Conditioned flavor aversion, 211
conditioned place preference
neonates
odor
reinforcement
stimulant drugs
Conditioned place preference
castration, 781
conditioned flavor aversion, 211
estrous, 781
mating behavior, 781
naloxone, 781
neonates, 211
odor, 211
reinforcement, 211
sexual reward, 781
stimulant drugs, 211
Continuous infusion, 131
antinociception
cross tolerance
spinal cord
Convulsions, drug induced, 159
amygdala
kindling
olfactory, bulb
pentylenetetrazol
seizures
sensitization
Corridor-type runway, 111
anxiolytic drugs
drug screening
Corticotropin-releasing hormone, 699
analgesia
novelty-induced behavior
Cross tolerance
antinociception, 131
continuous infusion, 131
monoamine/opioid interactions, 445
muscarinic receptors, 173
naloxone, 445
organophosphates, 173
QNB binding, 173
spinal analgesia, 445
spinal cord, 131
strain differences, 173
tolerance, 173, 445
Cyclazocine, 705
diuresis
kappa agonist, partial
mu-antagonist
non-opioid agonist
urinary output
Cyclic AMP, 619
atropine sulfate
footshock
immobilization
methylatropine nitrate
pituitary
prolactin
stress
[3H]Cyclohexyladenosine binding, 829
neuromodulator receptors
neurotransmitter receptors
stress, chronic

D1 receptors, 509
avoidance
operant responding
SCH 23390
[3H]DADLE binding, 203
chronic administration
electroconvulsive shock treatment
6-hydroxydopamine
imipramine
opioid δ receptor
reserpine
Defecation, 639
cats
thyrotropin-releasing hormone
Defensive behavior, 61
attack targets
ethanol
group formation
offensive behavior
social/agonistic interactions
Depression, drug induced, 287
chronic treatment
reserpine
5-HT receptors
5-hydroxytryptophan
Desipramine
anti-immobility effect, 417
chlorimipramine, 207
chronic administration, 417
hole board response, 207
perinatal undernutrition, 417
stress, 207
stress-induced behavior, 207
voluntary drug ingestion, 207
Diazepam
acute administration, 601
behavioral effects, 801
caffeine, 801
CGS 9896, 601
chronic administration, 601
dose effects, 801
drug comparisons, 601
drug interactions, 801

human studies, males, 801
tolerance, 601
withdrawal effects, 601
Differential effects
acute administration, 593
benzodiazepine receptor ligands, 247
CGS 8216, 145
chronic administration, 593
clomipramine, 593
drinking, 145, 247
eating, 145
food deprivation, 145
5-HT autoreceptors, 593
isotonic saline consumption, 247
naltrexone, 145
nialamide, 593
rats, males, 247
serotonin efflux, 593
water consumption, 247
water deprivation, 145
Difluoromethylornithine, 341
brain plasticity, experience dependent
environmental complexity
environmental impoverishment
polyamines
Diisopropylphosphofluoridate
acetylcholinesterase activity, 813
acute administration, 281
choline acetyltransferase activity, 813
muscarinic receptors, 813
nicotinic receptors, 813
recovery, 813
sex differences, 813
subacute administration, 281
tolerance development, 281
Direct enhancement, 709
CGS 8216
chlordiazepoxide
drug interactions
positive palatability
Ro 15-1788
Directional behavior, 527
d-amphetamine
rotational behavior
perseveration
spontaneous alternation
Discriminative properties, 719
food deprivation
morphine
reinforcing properties
Diuresis, 705
cyclazocine
kappa agonist, partial
mu-antagonist
non-opioid agonist
urinary output
DOPAC, 351
antidepressants
catecholamines
dopamine
drug comparisons
lesions, nucleus accumbens
muricide
nucleus accumbens
DOPAC/DA ratio
ACh formation, 305
dose-dependent effects, 305
hypothalamus, 585
locomotor activity, 305
neurochemical actions, 305
nicotine, 305
sham feeding, 585
sucrose, 585
time-dependent effects, 305
Dopamine
d-amphetamine, 821
antidepressants, 351
brain catecholamines, 613
brain monoamines, 821
catecholamines, 351
catecholamine turnover, 613
DOPAC, 351
dose differences, 821
drug comparisons, 351
drug interactions, 77, 765
lesions, nucleus accumbens, 351
locomotor activity, 765
locomotor activity, nocturnal, 821
long-lasting effects, 821
muricide, 351
muricide suppression, 77
nomifensine, 77
norepinephrine, 613
nucleus accumbens, 351, 765
opiates, 765
pregnancy, 613
pre-synaptic locus, 765
seizure susceptibility, 613
serotonin, 821
stereotyped behavior, 821
thiamine deficiency, 77
Dopamine agonists
amfonelic acid, 413
behavioral activation, 715
benzazepine enantiomers, 715
drug comparisons, 715
drug discrimination, 413
EEG activation, 715
grooming, 643
habenula nucleus, 643
locomotor activity, 643
rabbits, 715
rearing, 643
SCH 23388, 715
SCH 23390, 715
Dopamine antagonists, 123
dopamine autoreceptors
EEG slow wave activity
motor activity
sleep-wake activity
Dopamine autoreceptors, 123
dopamine antagonists
EEG slow wave activity
motor activity
sleep-wake activity
Dopamine D-1 receptors, 687
dopamine D-2 receptors
drinking
saline acceptance-rejection
SCH 23390
sulpiride
water deprivation
Dopamine D-2 receptors, 687
dopamine D-1 receptors
drinking
saline acceptance-rejection
SCH 23390
sulpiride
water deprivation
Dopamine receptor binding, 635
chronic administration
down-regulation
fluphenazine
lithium
muscarinic receptor binding
Dopamine receptor hypersensitivity, 223
autoreceptor blockade
neuroleptics
Dopamine receptors, 253
caudate nucleus
rabbit/rat comparisons
^{3}H-spiperone
^{3}H-spiperone binding
Dopaminergic properties, 265
α_1-adrenergic properties
B-HT290
morphine-withdrawal behavior
Dopaminergic supersensitivity, 661
haloperidol
locomotor activity
oral administration
^{3}H-spiroperidol binding
stereotypy
Dopaminergic system, 543
cataleptic behavior
cholinergic system
prostaglandin D_2
serotonergic system
Dose-dependent effects, 305
ACh formation
DOPAC/DA ratio
locomotor activity
neurochemical actions
nicotine
time-dependent effects
Dose differences, 821
d-amphetamine
brain monoamines
dopamine
locomotor activity, nocturnal
long-lasting effects
serotonin
stereotyped behavior
Dose effects, 801
behavioral effects
caffeine
diazepam
drug interactions
human studies, males
Dose related effects, 229
aggression
brain transmitters
footshock aggression
propranolol
Dose-response
biphasic effects, 65
FK 33824, 743
linear running, 743
locomotor activity, 65
opioids, 743
strain differences, 743
toluene inhalation, 65
wheel running activity, 743
Dose-response relationship, 757
adrenergic agonists
adrenergic antagonists
chickens
epinephrine
food intake
hepatic portal vein
vagotomy
Down-regulation, 635
chronic administration
dopamine receptor binding
fluphenazine
lithium

muscarinic receptor binding
Drinking
acquisition and maintenance, 677
acute administration, 431
angiotensin II, 431
antidipsogenic effect, 431
benzodiazepine receptor ligands, 247
bromocriptine, 431
CGS 8216, 145
cholinergic stimulation, 771
differential effects, 145, 247
dopamine D-1 receptors, 687
dopamine D-2 receptors, 687
eating, 145
estrogen pretreatment, 431
food deprivation, 145
isoproterenol, 431
isotonic saline consumption, 247
lateral hypothalamus, 771
M_1 muscarinic receptors, 771
M_2 muscarinic receptors, 771
naloxone, 677
naltrexone, 145
rats, males, 247
saline acceptance-rejection, 687
SCH 23390, 687
schedule-induced polydipsia, 677
sulpiride, 687
water consumption, 247
water deprivation, 145, 687
Drug
AHR602, 771
AHR6405, 771
(+)AJ 76 (cis-(+)-5-methoxy-1-methyl-2-(n-propylamino)tetralin), 123
alcohol, 29, 693, 749
amantadine hydrochloride, 543
amfonelic acid, 413
amitriptyline, 35, 153, 313
amphetamine, 167, 211, 413, 547, 731, 757, 765
d-ampehtamine, 7, 17, 527, 577, 827
(+)-amphetamine, 425
aniracetam, 183
antazoline, 639
apomorphine, 217, 223, 299, 413, 503, 715, 765, 771
apomorphine hydrochloride, 77, 543
apovincaminic acid, 183
atrophine, 475
atropine, 229, 327, 393, 639
atropine methyl nitrate, 229
atropine sulfate, 357, 543, 619
benserazide, 407
betaxolol, 11
bicuculline, 71
BM123, 475
BMY 25.368, 683
bramazocine, 705
bromocriptine, 431
caffeine, 381, 427, 801, 841
carbachol, 771
cathinone, 413, 547
cesium, 235
CGS 8216, 145, 247, 497, 709
CGS 9896, 247, 601
chlomipramine, 153, 207
chlordiazepoxide, 561, 577, 631, 709
chlorimipramine, 207
N-[2-chloroethyl]-N-2-bromobenzylamine, 217
p-chlorophenylalanine, 543
chlorpheniramine, 683
chlorproamzine, 639
cimetidine, 683
clenbuterol, 11
clomethiazole, 749
clomipramine, 543, 593
clonazepam, 247, 381
clonidine, 23, 373, 421, 437, 533, 731, 791
cocaine, 37, 211, 413, 453, 573, 835
co-dergocrine, 95
cola seeds, 841
cyclazocine, 705
4-DAMP, 771
2-deoxy-D[l-^{14}C]glucose, 95
desipramine, 11, 207, 417
desmethylimipramine, 35, 77
diazepam, 111, 601, 801
dicyclomine, 771
β-diethylaminoethyldiphenylpropylacetate, 671
difluoromethylornithine, 341
L-dihydroxyphenylalanine, 543
L-3,4-dihydroxyphenylalanine, 77
5,6-dihydroxytryptamine, 639
diisopropylfluorophosphate, 173, 281
diisopropylphosphofluoridate, 813
6,7-dimethoxy-4-ethyl-β- carboline-3-carboxylate, 381
1-(2,4-dimethoxyphenyl)-2-aminopropane, 547
1-(3,4-dimethoxyphenyl)-2-aminopropane, 547
dopamine, 271, 765
dopamine hydrochloride, 77
epinephrine, 491, 757
eserine, 393
estazolam, 521
ethanol, 61, 103
N-ethyl-acetylcholine aziridinium, 365
ethylcholine aziridinium ion, 357
N-ethyl-choline aziridinium, 365
etonitazine, 749
FG 7142, 247
FK 33824, 743
FLA-63
fluphenazine, 635
flurazepam, 521, 647
flurothyl, 71
formetanate, 119
haloperidol, 1, 37, 111, 223, 241, 265, 453, 509, 661
harmalan, 749
harman, 749
hemicholinium-3, 639
hexamethonium, 119, 305
B-HT920, 265
Hydergine®, 183
4-hydroxyclonidine, 437
6-hydroxydopamine, 77, 203, 639
(+)-3-[3-hydroxyphenyl]-N-n-propylpiperidine, 217
5-hydroxytryptophan, 287
iminodipropionitrite, 791
imipramine, 11, 35, 111, 203, 351
imipramine hydrochloride, 543
impromidine, 683
IPS-339, 11
isoproterenol, 431
ketamine, 23, 401
lisurid, 265
lithium, 235, 635
lorazepam, 521
LY 171555, 643, 715
mecamylamine, 305, 393, 639
MCNA343, 771
mescamylamine, 119
metergoline, 153
methamphetamine, 547
methcathinone, 547
methoxamine, 373
5-methoxy-N,N-dimethyltryptamine, 543
1-(2-methoxy-4,5-methylenedioxyphenyl)-2-aminopropane, 547
N-methyl atropine, 475
methylatropine nitrate, 619
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, 381
(3,4-methylenedioxymethamphetamine, 401
N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, 425
(+)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, 425
(−)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, 425
(±)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane, 425
methylscopolamine, 119
α-methyl-p-tyrosine, 291
methysergide, 327, 639
metoclopramide, 45, 223
mianserin, 351
midazolam, 749, 797
molindine, 731
monosodium glutamate, 503
morphine, 45, 131, 153, 539, 565, 607, 705, 719
muscimol, 49, 187
myelin basic protein, 851
naloxone, 131, 153, 167, 191, 199, 327, 437, 445, 515, 565, 705, 765, 781
naloxone hydrochloride, 677
naltrexone, 145, 483, 515
nialamide, 407, 593
nicotine, 259, 305, 393, 427
nisoxetine, 835
nomifensine, 77, 351
norcocaine, 573
norepinephrine, 131, 217, 533
nortriptyline, 153
oxotremorine, 173, 771
pemoline, 183
pentetrazol, 111
pentobarbital, 521, 647
pentylenetetrazol, 71, 159
phencyclidine, 23, 401, 671, 847
phenoxybenzamine hydrochloride, 543
phentolamine, 327, 373, 437, 491
1-(1-phenylcyclo-hexyl)4-hydroxypiperidine 671, 847
phenylephrine, 217, 373, 757
β-phenylethylamine, 199
1-(1-phenyl-4-hydroxcyclohexyl) piperidine 671, 847
phenylpropanolamine, 211, 321
physostigmine, 229, 553
picrotoxin, 49,
picrotoxinin. 381
pilocarpine, 327, 635, 771
pimozide, 731

piperoxane, 453
pirenzepine, 771
potassium, 235
prazosin, 265, 437, 791, 835
procaine, 453
propranolol, 229, 639
(+)propranolol, 229
(±)propranolol, 229
propranolol hydrochloride, 543
quinpirole hydrochloride, 643
^{3}H quinuclidinyl benzilate, 671
reserpine, 203, 287, 437, 453, 639
ritanserin, 333
Ro4-4601, 77
Ro 5-4864, 381
Ro15-1788, 111, 247, 381, 497, 631, 709, 797
rubidium, 235
RU 24213, 45
salbutamol, 229, 421, 757
SCH 23388, 715
SCH 23390, 45, 509, 687, 715
scopolamine, 119, 195, 313, 553, 771
serotonin, 445
SKF 38393, 45, 643, 715
^{3}H-spiperone, 253
ST-91, 437
ST-587, 437
sulpiride, 223, 687
telenzepine, 771
Δ^9-tetrahydrocannabinol, 141, 533
tetrahydronorharman (tetra-β-carboline), 749
L-threo-3,4-dihydroxyphenylserine, 407
toluene, 65
tracazolate, 111
1-(2,4,5-trimethoxyphenyl)-2-aminopropane, 547
d-tubocurare, 437
(+)-UH 232 (cis-(+)-5-methoxy-1-methyl-2-(di-n-propylamino)tetralin), 123
UM-272, 229
vincamine, 183
vinpocetine, 183
yohimbine, 265, 327, 373, 421, 437, 453, 639, 731, 791
zimelidine, 313, 351
zopiclone, 111, 247

Drug comparisons
acute administration, 601
alcohol, 749
alcohol preference, 749
antidepressants, 351
behavioral activation, 715
behavioral effects, 841
benzazepine enantiomers, 715
caffeine, 841
β-carbolines, 749
catecholamines, 351
catecholaminergic agonists, 731
catecholaminergic antagonists, 731
CGS 9896, 601
chronic administration, 601
cocaine, 573
cola seeds, 841
diazepam, 601
DOPAC, 351
dopamine, 351
dopamine agonists, 715
EEG activation, 715
electrical brain stimulation, 731
harmalan, 749
ketamine, 401
lesions, nucleus accumbens, 351
locomotor activity, 573
(3,4-methylenedioxymethamphetamine), 401
monkeys, 401
multiple schedule of performance, 401
muricide, 351
norcocaine, 573
nucleus accumbens, 351
operant behavior, complex, 401
phencyclidine, 401
psychostimulants, 841
quantitive determination, 731
rabbits, 715
repeated acquisition, 401
rewarding efficacy, 731
route of administration, 573
SCH 23388, 715
SCH 23390, 715
sub-chronic treatment, 841
tolerance, 601
ultradian rhythm, 749
withdrawal effects, 601

Drug discrimination
amfonelic acid, 413
dopamine agonists, 413
methcathinone, 547
naloxone, 199
β-phenylethylamine, 199
rate suppressant effects, 199
spontaneous activity, 547
stimulus generalization, 547
stimulus properties, 199

Drug interaction
acute administration, 153
additive effects, 427
amino acid precursors, 427
amphetamine, 167
analgesia, 153
antidepressants, 153
atropine, 475
behavioral effects, 801
benzodiazepine antagonists, 631
BM123, 475
caffeine, 427, 801
catecholamine release, 427
CGS 8216, 709
chlordiazepoxide, 631, 709
chronic administration, 153
diazepam, 801
direct enhancement, 709
dopamine, 77, 765
dose effects, 801
endogenous opioid system, 153
beta-endorphin concentrations, 153
exploration, 631
fixed-interval schedule, 167
fixed-ratio schedule, 167
habituation, 631
human studies, males, 801
ketamine, 23
locomotor activity, 427, 631, 765
N-methyl atropine, 475
muscarinic receptor, 475
muricide suppression, 77
naloxone, 167
nicotine, 427
nomifensine, 77
nucleus accumbens, 765
opiates, 765
phencyclidine, 23
positive palatability, 709
pre-synaptic locus, 765
radial maze performance, 23
reversible association, 475
righting reflex, 23
Ro 15-1788, 631, 709
serotoninergic system, 153
thiamine deficiency, 77

Drug screening, 111
corridor-type runway
anxiolytic drugs

Eating
anorexia, 5-HT induced, 333
appetite, 321
CGS 8216, 145
differential effects, 145
drinking, 145
feeding behavior, 515
food deprivation, 145
food intake, 321
human studies, females, 321
5-hydroxytryptamine 333
meal patterns, 515
naloxone, 515
naltrexone, 145, 515
phenylpropanolamine, 321
ritanserin, 333
satiety, 515
water deprivation, 145

EEG activation, 715
behavioral activation
benzazepine enantiomers
dopamine agonists
drug comparisons
rabbits
SCH 23388
SCH 23390

EEG slow wave activity, 123
dopamine antagonists
dopamine autoreceptors
motor activity
sleep-wake activity

Electrical activity, 357
behavioral effects
ethylcholine aziridinium ion
hippocampus
rhythmical slow activity

Electrical brain stimulation, 731
catecholaminergic agonists
catecholaminergic antagonists
drug comparisons
quantitative determination
rewarding efficacy

Electroconvulsive shock treatment, 203
chronic administration
[^{3}H]DADLE binding
6-hydroxydopamine
imipramine
opioid δ receptor
reserpine

Electrophysiological correlates, 299
apomorphine
sniffing
stereotyped behavior

Endogenous opioid system, 153
acute administration
analgesia
antidepressants

chronic administration
drug interaction
beta-endorphin concentrations
serotoninergic system
Entopeduncular nucleus, 49
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
β-Endorpin, 57
analgesic effect
oxytocin
tolerance
β-Endorphin concentrations, 153
acute administration
analgesia
antidepressants
chronic administration
drug interaction
endogenous opioid system
serotoninergic system
Environmental complexity, 341
brain plasticity, experience dependent
difluoromethylornithine
environmental impoverishment
polyamines
Environmental familiarity, 141
adaptation
behavioral effects
prior drug experience
delta-9-tetrahydrocannabinol
Environmental impoverishment, 341
brain plasticity, experience dependent
difluoromethylornithine
environmental complexity
polyamines
Epineprhine, 757
adrenergic agonists
adrenergic antagonists
chickens
dose-response relationship
food intake
hepatic portal vein
vagotomy
Estrogen pretreatment, 431
acute administration
angiotensin II
antidipsogenic effect
bromocriptine
drinking
isoproterenol
Estrous, 781
castration
conditioned place preference
mating behavior
naloxone
sexual reward
Estrous cycle, 37
cocaine
haloperidol
neuroleptic activity
ovariectomy
self-administration
Ethanol
adenylate cyclase, 693
attack targets, 61
chronic administration, 693
defensive behavior, 61
eye tracking, 103
group formation, 61
in vitro, 693
liquid diet, 693
monkey/human comparisons, 103
offensive behavior, 61
smooth pursuit eye movements, 103
social/agonistic interactions, 61
tolerance, 693
Ethylcholine aziridinium ion, 357
behavioral effects
electrical activity
hippocampus
rhythmical slow activity
Experimental allergic encephalomyelitis, 851
catecholamine concentrations
spleen
Exploration, 631
benzodiazepine antagonists
chlordiazepoxide
drug interactions
habituation
locomotor activity
RO 15-1788
Eye tracking, 103
ethanol
monkey/human comparisons
smooth pursuit eye movements

Feeding behavior, 515
eating
meal patterns
naloxone
naltrexone
satiety
Fixed-interval schedule, 167
amphetamine
drug interaction
fixed-ratio schedule
naloxone
Fixed-ratio schedule, 167
amphetamine
drug interaction
fixed-interval schedule
naloxone
FK 33824, 743
dose-response
linear running
opioids
strain differences
wheel running activity
FLA-63, 407
benserazide
L-threo-3,4-dihydroxyphenylserine
locomotor activity
nialamide
norepinephrine levels
[^{3}H]Flunitrazepam binding sites, 35
antidepressants
benzodiazepine receptors
route of administration
Fluphenazine, 635
chronic administration
dopamine receptor binding
down-regulation
lithium
muscarinic receptor binding
Flurazepam, 647
cats
pentobarbital
respiration
respiratory neurons
Food deprivation
catecholamine levels, 271
catecholamine turnover, 271
CGS 8216, 145
differential, 145
drinking, 145
discriminative properties, 719
eating, 145
hypothalamus, 271
α-methyl-p-tyrosine, 271
morphine, 719
naltrexone, 145
reinforcing properties, 719
water deprivation, 145
Food intake
adrenergic agonist, 757
adrenergic antagonists, 757
appetite, 321
chickens, 757
dose-response relationship, 757
eating, 321
epinephrine, 757
hepatic portal vein, 757
human studies, females, 321
phenylpropanolamine, 321
vagotomy, 757
Footshock
d-amphetamine, 17
atropine sulfate, 619
concentration variations, 653
cyclic AMP, 619
immobilization, 619
methylatropine nitrate, 619
norepinephrine, 653
pituitary, 619
prolactin, 619
rotational behavior, 17
rotational bias, 17
sex differences, 17
stress, 619
stress, chronic, 653
Footshock aggression, 229
aggression
brain transmitters
dose related effects
propranolol
Forebrain, 389
alcohol nonpreferring rats
alcohol preferring rats
monoamine content
strain differences
Formetanate, 119
acetylcholinesterase inhibition
operant behavior
schedule-controlled responding

GABA agonists, 463
analgesia
GABA-transaminase inhibitors
noradrenergic pathways
GABA antagonists, 71
seizure susceptibility
selective breeding
strain differences
GABA levels, brain, 83

age differences
aggression, shock-induced
inbred mice
strain differences
GABA-transaminase inhibitors, 463
analgesia
GABA agonists
noradrenergic pathways
Gabergic projections, pallidal, 49
entopedunicular nucleus
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
Gabergic projections, striatal, 49
entopeduncular nucleus
gabergic projections, pallidal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
Gastric secretion, 293
body weight gain
gastric ulceration
mast cells
stress
zinc deficiency
Gastric ulceration, 293
body weight gain
gastric secretion
mast cells
stress
zinc deficiency
Grooming, 643
dopamine agonists
habenula nucleus
locomotor activity
rearing
Group formation, 61
attack targets
defensive behavior
ethanol
offensive behavior
social/agonistic interactions

H2 antagonists, 683
histamine receptors
locomotor activity
Habenula nucleus, 643
dopamine agonists
grooming
locomotor activity
rearing
Habituation
d-amphetamine, 7
benzodiazepine antagonists, 631
chlordiazepoxide, 631
drug interactions, 631
exploration, 631
locomotor activity, 631
rearing, off-wall, 7
rearing, on-wall, 7
RO 15-1788, 631
Haloperidol
avoidance performance, 241
chronic administration, 1
cocaine, 37
cognitive effects, 1
dopaminergic supersensitivity, 661
estrous cycle, 37
latent inhibition, 241
locomotor activity, 661
motor effects, 1
neuroleptic activity, 37
oral administration, 661
oral movements, 1
ovariectomy, 37
self-administration, 37
^{3}H-spiroperidol binding, 661
stereotypy, 661
Harmalan, 749
alcohol
alcohol preference
β-carbolines
drug comparisons
ultradian rhythm
Hepatic portal vein, 757
adrenergic agonists
adrenergic antagonists
chickens
dose-response relationship
epinephrine
food intake
vagotomy
Heptyl, 625
acetylcholinesterase
cholinesterase inhibition
locomotor activity
memory
physostigmine analogues
Hibernation, 565
circannual rhythm
opiates
seasonal difference
squirrels
thermoregulation
Hindlimb scratching, 327
muscarinic receptors
neurokinins
pilocarpine
route of administration
Hippocampus
behavioral effects, 357, 421
cholinergic activity, 553
clonidine, 421
electrical activity, 357
ethylcholine aziridinium ion, 357
intrahippocampal administration, 421
odor aversions, 553
rhythmical slow activity, 357
salbutamol, 421
taste aversions, 553
yohimbine, 421
Histimine receptors, 683
H2 antagonists
locomotor activity
Hole board response, 207
chlorimipramine
desipramine
stress
stress-induced behavior
voluntary drug ingestion
Hormone
ACTH, 277
epinephrine, 271
estradiol benzoate, 431
estrogen, 393, 431
17-β-estradiol benzoate, 37
2-hydroxyestradiol, 37
noradrenaline, 351
norepinephrine, 271, 373, 407, 445, 613, 653, 835
progesterone, 393
prostaglandin D_2, 543
testosterone, 533
5-HT autoreceptors, 593
acute administration
chronic administration
clomipramine
differential effects
nialamide
serotonin efflux
5-HT receptors, 287
chronic treatment
depression, drug induced
reserpine
5-hydroxytryptophan
Human studies, females, 321
appetite
eating
food intake
phenylpropanolamine
Human studies, males
acute administration, 29
alcohol, 29
behavioral effects, 801
behavioral impairment, 29
caffeine, 801
diazepam, 801
dose effects, 801
drug interactions, 801
learning, 29
tolerance, 29
6-Hydroxydopamine, 203
chronic administration
[^{3}H]DADLE binding
electroconvulsive shock treatment
imipramine
opioid δ receptor
reserpine
5-Hydroxytryptamine, 333
anorexia, 5-HT induced
eating
ritanserin
5-Hydroxytryptophan, 287
chronic treatment
depression, drug induced
reserpine
5-HT receptors
Hyperglycemia, stress-induced, 491
blood glucose responses
plasma insulin responses
sympathetic nervous system
Hypophysectomy
ACTH, 277, 503
adrenocorticotropic hormone, 503
apomorphine, 503
monosodium glutamate, 503
penile erection, 277, 503
yawning, 277, 503
Hypothalamus
acute exposure, 533

catecholamine levels, 271
catecholamine turnover, 271
clonidine, 533
DOPAC/DA ratios, 585
food deprivation, 271
in vitro, 533
in vivo, 533
α-methyl-p-tyrosine, 271
sham feeding, 585
sucrose, 585
testes, 533
testosterone, 533
Δ^9-tetrahydrocannabinol, 533
Hypothermia, 373
anterior hypothalamus/preoptic area
cats
α-noradrenergic receptors
thermoregulation

Iminodipropionitrile, 791
alpha-adrenoceptors
clonidine
prazosin
spasmodic syndrome, drug-induced
Imipramine, 203
chronic administration
[^{3}H]DADLE binding
electronconvulsive shock treatment
6-hydroxydopamine (6-OHDA)
opioid δ receptor
reserpine
Immobilization, 619
atropine sulfate
cyclic AMP
footshock
methylatropine nitrate
pituitary
prolactin
stress
Immobilization stress, 259
α_2-adrenoceptors
β-adrenoceptors
chronic administration
muscarinic cholinoceptors
nicotine
stress, repeated
Inbred mice, 83
age differences
aggression, shock-induced
GABA levels, brain
strain differences
Inbred strains, 381
caffeine
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate
picrotoxinin
Ro 5-4864
seizure susceptibility
Inferotemporal cortex, 89
neuronal membrane proteins
prefrontal cortex
visual discrimination
Intrahippocampal administration, 421
behavioral effects
clonidine
hippocampus
salbutamol
yohimbine
Intruder treatment, 577
d-amphetamine
chlordiazepoxide
maternal aggression
maternal treatment
opponent size
In vitro
acute exposure, 533
adenylate cyclase, 693
alkali metals, 235
chronic administration, 693
clonidine, 533
ethanol, 693
hypothalamus, 533
in vivo, 235, 533
liquid diet, 693
lithium, 235
mechanism of action, 235
superoxide dismutase, 235
testes, 533
testosterone, 533
Δ^9-tetrahydrocannabinol, 553
tolerance, 693
In vivo
acute exposure, 533
alkali metals, 235
clonidine, 533
cocaine, 453
hypothalamus, 533
in vitro, 235, 533
lithium, 235
mechanism of action, 235
monoaminergic neurotransmission, 453
phencyclidine, 671, 847
phencyclidine metabolites, 671
^{3}H quinuclidinyl benzilate binding, 671, 847
superoxide dismutase, 235
testes, 533
testosterone, 533
Δ^9-tetrahydrocannabinol, 533
IPS-339, 11
beta-adrenergic agonists
β1 receptors
β2 receptors
betaxolol
chronic administration
clenbuterol
spontaneous motor activity
Isolation distress, 483
pain threshold
sucrose
vocalizations
Isoproterenol, 431
acute administration
angiotensin II
antidipsogenic effect
bromocriptine
drinking
estrogen pretreatment
Isotonic saline consumption, 247
benzodiazepine receptor ligands
differential effects
drinking
rats, males
water consumption

Jaw opening reflex, 437
alpha$_2$ adrenoceptors
clonidine
nociception
rabbit/rat comparisons

Kappa agonist, partial, 705
cyclazocine
diuresis
mu-antagonist
non-opioid agonist
urinary output
Ketamine
drug comparisons, 401
drug interactions, 23
(3,4-methylenedioxymethamphetamine, 401
monkeys, 401
multiple schedule of performance, 401
operant behavior, complex, 401
phencyclidine, 23, 401
radial maze performance, 23
repeated acquisition, 401
righting reflex, 23
Kindling, 159
amygdala
convulsions, drug induced
olfactory bulb
pentylenetetrazol
seizures
sensitization
Kinetics, 313
age differences
antidepressants
memory, short-term

Latent inhibition, 241
avoidance performance
haloperidol
Lateral hypothalamus, 771
cholinergic stimulation
drinking
M_1 muscarinic receptors
M_2 muscarinic receptors
Learning, 29
acute administration
alcohol
behavioral impairment
human studies, males
tolerance
Learning and memory, 95
age differences
co-dergocrine
local cerebral glucose utilization
locus ceruleus
maze performance
Lesions, 5,7-dihydroxytryptamine, 607
lesions, nucleus accumbens
self-administration, intravenous
serotonergic innervation
Lesions, electrolytic, 187
antinociception
muscimol
self-injurious behavior
stereotyped behavior substantia nigra
superior colliculus
ventromedial thalamus
Lesions, midbrain raphe nucleus, 725
biogenic amines
lesions, nucleus accumbens
monoamine content
muricide
olfactory bulbectomy
Lesions, nucleus accumbens
antidepressants, 351
biogenic amines, 725
catecholamines, 351
DOPAC, 351

dopamine, 351
drug comparisons, 351
lesions, 5,7-dihydroxytryptamine, 607
lesions, midbrain raphe nucleus, 725
monoamine content, 725
muricide, 351, 725
nucleus accumbens, 351
olfactory bulbectomy, 725
self-administration, intravenous, 607
serotonergic innervation, 607
Linear running, 743
dose-response
FK 33824
opioids
strain differences
wheel running activity
Liquid diet, 693
adenylate cyclase
chronic administration
ethanol
in vitro
tolerance
Lithium
alkali metals, 235
chronic administration, 635
dopamine receptor binding, 635
down-regulation, 635
fluphenazine, 635
in vitro, 235
in vivo, 235
mechanism of action, 235
muscarinic receptor binding, 635
superoxide dismutase, 235
Local cerebral glucose utilization, 95
age differences
co-dergocrine
learing and memory
locus ceruleus
maze performance
Locomotor activity
acetylcholinesterase, 625
ACh formation, 305
additive effects, 427
aggression, drug induced, 217
amino acid precursors, 427
amygdala, 217
analgesia, 539
benserazide, 407
benzodiazepine antagonists, 631
biphasic effects, 65
caffeine, 427
catecholamine release, 427
chlordiazepoxide, 631
cholinesterase inhibition, 625
cocaine, 573
DOPAC/DA ratio, 305
dopamine, 765
dopamine agonists, 643
dopaminergic supersensitivity, 661
dose-dependent effects, 305
dose-response, 65
drug comparisons, 573
drug interactions, 427, 631, 765
entopeduncular nucleus, 49
exploration, 631
FLA-63, 407
gabergic projections, pallidal, 49
gabergic projections, striatal, 49
grooming, 643
habenula nucleus, 643
habituation, 631
haloperidol, 661
heptyl, 625
histamine receptors, 683
H2 antagonists, 683
memory, 625
metabolic rate, 195
morphine, 539
motivational effects, 49
motor effects, 49
muscimol, 49
neurochemical actions, 305
nialamide, 407
nicotine, 305, 427
norcocaine, 573
norepinephrine, 217
norepinephrine levels, 407
nucleus accumbens, 765
opiates, 765
oral administration, 661
post-weaning exposure, 539
physostigmine analogues, 625
picrotoxin, 49
pre-synaptic locus, 765
pre-weaning exposure, 539
rearing, 643
RO 15-1788, 631
route of administration, 573
scopolamine, 195
^{3}H-spiroperidol binding, 661
stereotypy, 661
subthalamic nucleus, 49
L-threo-3,4-dihydroxyphenylserine, 407
time-dependent effects, 305
toluene inhalation, 65
variable-interval hypothalamic self-stimulation, 49
ventral globus pallidus, 49
ventromedial thalamus, 49
Locomotor activity, backward walking, 45
catalepsy
morphine
RU 24213
SKF 38393
Locomotor activity, nocturnal, 821
d-amphetamine
brain monoamines
dopamine
dose differences
long-lasting effects
serotonin
stereotyped behavior
Locus ceruleus, 95
age differences
co-dergocrine
learning and memory
local cerebral glucose utilization
maze performance
Long-lasting effects, 821
d-amphetamine
brain monoamines
dopamine
dose differences
locomotor activity, nocturnal
serotonin
stereotyped behavior
Lordosis, 393
nicotine
nicotinic cholinergic transmission
ovariectomy
rats, females
route of administration
sexual receptivity
M_1 muscarinic receptors, 771
cholinergic stimulation
drinking
lateral hypothalamus
M_2 muscarinic receptors
M_2 muscarinic receptors, 771
cholinergic stimulation
drinking
lateral hypothalamus
M_1 muscarinic receptors
Mast cells, 293
body weight gain
gastric secretion
gastric ulceration
stress
zinc deficiency
Maternal aggression, 577
d-amphetamine
chlordiazepoxide
intruder treatment
maternal treatment
opponent size
Maternal treatment, 577
d-amphetamine
chlordiazepoxide
intruder treatment
maternal aggression
opponent size
Mating behavior, 781
castration
conditioned place preference
estrous
naloxone
sexual reward
Maze performance, 95
age differences
co-dergocrine
learning and memory
local cerebral glucose utilization
locus ceruleus
Meal patterns, 515
feeding behavior
eating
naloxone
naltrexone
satiety
Mechanism of action, 235
alkali metals
in vitro
in vivo
lithium
superoxide dismutase
Memory
acetylcholinesterase, 625
cholinesterase inhibition, 625
heptyl, 625
locomotor activity, 625
passive avoidance, 183
physostigmine analogues, 625
retrieval, 183
vinpocetine, 183
Memory, reference, 365
choline uptake
memory, working
N-ethyl-acetylcholine aziridinium
Memory, short-term, 313
age differences
antidepressants
kinetics
Memory, working, 365
choline uptake
memory, references

N-ethyl-acetylcholine aziridinium
Metabolic rate, 195
locomotor activity
scopolamine
Methcathinone, 547
drug discrimination
spontaneous activity
stimulus generalization
N-Methyl atropine, 475
atropine BM123
drug interaction
muscarinic receptors
reversible receptors
Methylatropine nitrate, 619
atropine sulfate
cyclic AMP
footshock
immobilization
pituitary
prolactin
stress
Methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, 381
caffeine
inbred strains
picrotoxinin
Ro 5-4864
seizure susceptibility
(3,4-Methylenedioxymethamphetamine), 401
drug comparisons
ketamine
monkeys
multiple schedule of performance
operant behavior, complex
phencyclidine
repeated acquisition
N-Methyl-1-(3,4-methylene-dioxyphenyl)-2-aminopropane, 425
behavioral-potency comparisons
phenylisopropyl amines
schedule-controlled responding
α-Methyl-p-tyrosine, 271
catecholamine levels
catecholamine turnover
food deprivation
hypothalamus
Method
electrocorticogram, 299
high performance liquid chromatography with electrochemical detection, 725, 821, 851
high performance liquid chromatography with fluorescence detection, 427
high pressure liquid chromatography with electrochemical detection, 351, 607, 613
radioimmunoassay, 619, 661
Midazolam, 797
physical dependence
sceduled-induced polydipsia
self-administration, oral
Monkey/human comparisons, 103
ethanol
eye-tracking
smooth pursuit eye movements
Monkeys
benzodiazepines, 521
chronic administration, 191
drug comparisons, 401
ketamine, 401
(3,4-methylenedioxymetham-phetamine), 401
multiple schedule of performance, 401
naloxone, 191
norepinephrine, 835
operant behavior, complex, 401
phencyclidine, 401
psychomotor stimulants, 835
rate of responding, 191
reinforcing effects, 835
repeated acquisition, 401
self-administration, 521, 835
shock titration, 191
Monoamine content
alcohol nonpreferring rats, 389
alcohol preferring rats, 389
biogenic amines, 725
forebrain, 389
lesions, midbrain raphe nucleus, 725
lesions, nucleus accumbens, 725
muricide, 725
olfactory bulbectomy, 725
strain differences, 389
Monoamine/opioid interactions, 445
cross tolerance
naloxone
spinal analgesia
tolerance
Monoaminergic neurotransmission, 453
cocaine
in vivo
Monosodium glutamate, 503
adrenocorticotropic hormone
apomorphine
hypophysectomy
penile erection
yawning
Morphine
analgesia, 539
catalepsy, 45
discriminative properties, 719
food deprivation, 719
locomotor activity, 539
locomotor activity, backward walking, 45
post-weaning exposure, 539
pre-weaning exposure, 539
reinforcing properties, 719
RU 24213, 45
SKF 38393, 45
Morphine-withdrawal behavior, 265
α_1-adrenergic properties
B-HT290
dopaminergic properties
Motivational effects, 49
entopedunucular nucleus
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
Motor activity, 123
dopamine antagonist
dopamine autoreceptors
EEG slow wave activity
sleep-wake activity
Motor effects
chronic administration, 1
cognitive effects, 1
entopeduncular nucleus, 49
gabergic projections, pallidal, 49
gabergic projections, striatal, 49
haloperidol, 1
locomotor activity, 49
motivational effects, 49
muscimol, 49
oral movements, 1
picrotoxin, 49
subthalamic nucleus, 49
variable-interval hypothalamic self-stimulation, 49
ventral globus pallidus, 49
ventromedial thalamus, 49
Mu-antagonist, 705
cyclazocine
diuresis
kappa agonist, partial
non-opioid agonist
urinary output
Multiple schedule of performance, 401
drug comparisons
ketamine
(3,4-methylenedioxymetham-phetamine)
monkeys
operant behavior, complex
phencyclidine
repeated acquisition
Muricide
antidepressants, 351
biogenic amines, 725
catecholamines, 351
DOPAC, 351
dopamine, 77 351
drug comparisons, 351
drug interaction, 77
lesions, midbrain raphe nucleus, 725
lesions, nucleus accumbens, 351, 725
monoamine content, 725
nomifensine, 77
nucleus accumbens, 351
olfactory bulbectomy, 725
thiamine deficiency, 77
Muscarinic cholinoceptors, 259
α_2-adrenoceptors
β-adrenoceptors
chronic administration
immobilization stress
nicotine
stress, repeated
Muscarinic receptor binding, 635
chronic administration
dopamine receptor binding
down-regulation
fluphenazine
lithium
Muscarinic receptors
acetylcholinesterase activity, 813
atropine, 475
BM123
choline acetyltransferase activity, 813
cross-tolerance, 173
diisopropylphosphofluoridate, 813
drug interaction, 475
hindlimb scratching, 327
N-methyl atropine, 475
neurokinins, 327

nicotinic receptors, 813
organophosphates, 173
pilocarpine, 327
QNB binding, 173
recovery, 813
reversible association, 475
route of administration, 327
sex differences, 813
strain differences, 173
tolerance, 173
Muscimol
antinociception, 187
entopeduncular nucleus, 49
gabergic projections, pallidal, 49
gabergic projections, striatal, 49
lesions, electrolytic, 187
locomotor activity, 49
motivational effects, 49
motor effects, 49
picrotoxin, 49
self-injurious behavior, 187
stereotyped behavior, 187
substantia nigra, 187
subthalamic nucleus, 49
superior colliculus, 187
variable-interval hypothalamic self-stimulation, 49
ventral globus pallidus, 49
ventromedial thalamus, 49, 187

Naloxone
acquisition and maintenance, 677
amphetamine, 167
castration, 781
chronic administration, 191
conditioned place preference, 781
cross tolerance, 445
drinking, 677
drug discrimination, 199
drug interaction, 167
eating, 515
estrous, 781
feeding behavior, 515
fixed-interval schedule, 167
fixed-ratio schedule, 167
mating behavior, 781
meal patterns, 515
monkeys, 191
monoamine/opioid interactions, 445
naltrexone, 515
β-phenylethylamine, 199
rate of responding, 191
rate suppressant effects, 199
satiety, 515
schedule-induced polydipsia, 677
sexual reward, 781
shock titration, 191
spinal analgesia, 445
stimulus properties, 199
tolerance, 445
Naltrexone
CGS 8216, 145
differential effects, 145
drinking, 145
eating, 145, 515
feeding behavior, 515
food deprivation, 145
meal patterns, 515
naloxone, 515
satiety, 515
water deprivation, 145

Neonates, 211
conditioned flavor aversion
conditioned place preference
odor
reinforcement
stimulant drugs
N-ethyl-acetylcholine aziridinium, 365
choline uptake
memory, reference
memory, working
Neurochemical actions, 305
ACh formation
DOPAC/DA ratio
dose-dependent effects
locomotor activity
nicotine
time-dependent effects
Neurokinins, 327
hindlimb scratching
muscarinic receptors
pilocarpine
route of administration
Neuroleptic activity, 37
cocaine
estrous cycle
haloperidol
ovariectomy
self-administration
Neuroleptics, 223
autoreceptor blockade
dopamine receptor hypersensitivity
Neuromodulator receptors, 829
[^{3}H]cyclohexyladenosine binding
neurotransmitter receptors
stress, chronic
Neuronal membrane proteins, 89
inferotemporal cortex
prefrontal cortex
visual discrimination
Neurotransmitter receptors, 829
[^{3}H]cyclohexyladenosine binding
neuromodulator receptors
stress, chronic
Nialamide
acute administration, 593
benserazide, 407
chronic administration, 593
clomipramine, 593
differential effects, 593
L-threo-3,4-dihydroxyphenylserine, 407
FLA-63, 407
5-HT autoreceptors, 593
locomotor activity, 407
norepinephrine levels, 407
serotonin efflux, 593
Nicotinic cholinergic transmission, 393
lorodosis
nicotine
ovariectomy
rats, females
route of administration
sexual receptivity
Nicotinic receptors, 813
acetylcholinesterase activity
choline acetyltransferase activity
diisopropylphosphofluoridate
muscarinic receptors
recovery
sex differences
Nicotine
ACh formation, 305
additive effects, 427
α_2-adrenoceptors, 259
β-adrenoceptors, 259
amino acid precursors, 427
caffeine, 427
catecholamine release, 427
chronic administration, 259
DOPAC/DA ratio, 305
dose-dependent effects, 305
drug interactions, 427
immobilization stress, 259
locomotor activity, 305, 427
lordosis, 393
muscarinic cholinoceptors, 259
neurochemical action, 305
nicotinic cholinergic transmission, 393
ovariectomy, 393
rats, females, 393
route of administration, 393
sexual receptivity, 393
stress, repeated, 259
time-dependent effects, 305
Nociception, 437
α_2 adrenoceptors
clonidine
jaw opening reflex
rabbit/rat comparisons
Nomifensine, 77
dopamine
drug interaction
muricide suppression
thiamine deficiency
Non-opioid agonist, 705
cyclazocine
diuresis
kappa agonist, partial
mu-antagonist
urinary output
Noradrenergic pathways, 463
analgesia
GABA agonists
GABA-transaminase inhibitors
α-Noradrenergic receptors, 373
anterior hypothalamus/preoptic area
cats
hypothermia
thermoregulation
Norcocaine, 573
cocaine
drug comparisons
locomotor activity
route of administration
Norepinephrine
aggression, drug induced, 217
amygdala, 217
brain catecholamines, 613
catecholamine turnover, 613
concentration variations, 653
dopamine, 613
footshock, 653
locomotor activity, 217
monkeys, 835
pregnancy, 613
psychomotor stimulants, 835
reinforcing effects, 835
seizure susceptibility, 613
self-administration, 835
stress, chronic, 653
Norepinephrine levels, 407
benserazide
L-threo-3,4-dihydroxyphenylserine
FLA-63

locomotor activity
norepinephrine levels
Novelty-induced behavior, 699
analgesia
corticotropin-releasing hormone
Nucleus accumbens
antidepressants, 351
catecholamines, 351
DOPAC, 351
dopamine, 351, 765
drug comparisons, 351
drug interactions, 765
lesions, nucleus accumbens, 351
locomotor activity, 765
nucleus accumbens, 351
opiates, 765
pre-synaptic locus, 765

Odor, 211
conditioned flavor aversion
conditioned place preference
neonates
reinforcement
stimulant drugs
Odor aversions, 553
cholinergic activity
hippocampus
taste aversions
Offensive behavior, 61
attack targets
defensive behavior
ethanol
group formation
social/agonistic interactions
Olfactory bulb, 159
amygdala
convulsions, drug induced
kindling
pentylenetetrazol
seizures
sensitization
Olfactory bulbectomy, 725
biogenic amines
lesions, midbrain raphe nucleus
lesions, nucleus accumbens
monoamine content
muricide
Operant behavior, 119
acetylcholinesterase inhibition
formetanate
schedule-controlled responding
Operant-behavior, complex, 401
drug comparisons
ketamine
(3,4-methylenedeoxymetham-
phetamine)
monkeys
multiple schedule of performance
phencyclidine
repeated acquisition
Operant responding, 509
avoidance
D1 receptors
SCH 23390
Opiates
circannual rhythm, 565
dopamine, 765
drug interactions, 765
hibernation, 565
locomotor activity, 765
nucleus accumbens, 765
pre-synaptic locus, 765
seasonal difference, 565
squirrels, 565
thermoregulation, 565
Opioid δ receptor, 203
chronic administration
[^{3}H]DADLE binding
electronconvulsive shock treatment
6-hydroxydopamine
imipramine
reserpine
Opioids, 743
dose-response
FK 33824
linear running
strain differences
wheel running activity
Opponent size, 577
d-amphetamine
chlordiazepoxide
intruder treatment
maternal aggression
maternal treatment
Oral administration, 661
dopaminergic supersensitivity
haloperidol
locomotor activity
^{3}H-spiroperidol binding
stereotypy
Oral movements, 1
chronic administration
cognitive effects
haloperidol
motor effects
Organophosphates, 173
cross-tolerance
muscarinic receptors
QNB binding
strain differences
tolerance
Ovariectomy
cocaine, 37
estrous cycle, 37
haloperidol, 37
lordosis, 393
neuroleptic activity, 37
nicotine, 393
nicotinic cholinergic transmission, 393
rats, females, 393
route of administration, 393
self-administration, 37
sexual receptivity, 393
Oxytocin, 57
analgesic effect
β-endorphin
tolerance

Pain threshold, 483
isolation distress
sucrose
vocalizations
Palatability, 497
benzodiazepine receptors
CGS 8216
sham feeding
Passive avoidance, 183
memory
retrieval
vinpocetine
Penile erection
ACTH 277, 503
adrenocorticotropic hormone, 503
apomorphine, 503
hypophysectomy, 277, 503
monosodium glutamate, 503
yawning, 277, 503
Pentobarbital, 647
cats
flurazepam
respiration
respiratory neurons
Pentylenetetrazol, 159
amygdala
convulsions, drug induced
kindling
olfactory bulb
seizures
sensitization
Peptide
adrenocorticotropic hormone, 503
angiotensin II, 431
corticotropin-releasing hormone, 699
[D-Ala^2]-Met-enkephalinamide, 565
[D-Pro^2,D-Trp^{6,8},Nle^{10}]-NK, 327
[D-Pro^2,D-Trp^{7,9}]-SP, 327
β-endorphin, 57
luteinizing hormone-releasing
hormone, 533
oxytocin, 57
thyrotropin-releasing hormone, 639
Perinatal undernutrition, 417
anti-immobility effect
chronic administration
desipramine
Perseveration, 527
d-amphetamine
directional behavior
rotational behavior
spontaneous alternation
Phencyclidine, 23
drug comparisons, 401
drug interactions, 23
in vivo administration, 671, 847
ketamine, 23, 401
(3,4-methylenedioxymetham-
phetamine, 401
monkeys, 401
multiple schedule of performance, 401
operant behavior, complex, 401
radial maze performance, 23
phencyclidine metabolites, 671, 847
repeated acquisition, 401
righting reflex, 23
^{3}H quinuclidinyl benzilate binding, 671,
847
Phencyclidine metabolites
in vivo, 671, 847
phencyclidine, 671, 847
^{3}H quinuclidinyl benzilate binding, 671,
847
β-Phenylethylamine, 199
drug discrimination
naloxone
rate suppressant effects
stimulus properties
Phenylisopropylamines, 425
behavioral-potency comparison
N-methyl-1-(3,4-methylenedioxy-
phenyl)-2-aminopropane
schedule-controlled responding
Phenylpropanolamine, 321
human studies, females
appetite

eating
food intake
Physical dependence, 797
midazolam
scheduled-induced polydipsia
self-administration, oral
Physostigmine analogues, 625
acetylcholinesterase
cholinesterase inhibition
heptyl
locomotor activity
memory
Picrotoxin, 49
entopenduncular nucleus
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
Picrotoxinin, 381
caffeine
inbred strains
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate
Ro 5-4864
seizure susceptibility
Pilocarpine, 327
hindlimb scratching
muscarinic receptors
neurokinins
route of administration
Pituitary, 619
atropine sulphate
cyclic AMP
footshock
immobilization
methylatropine nitrate
prolactin
stress
Plasma insulin responses, 491
blood glucose responses
hyperglycemia, stress-induced
sympathetic nervous system
Polyamines, 341
brain plasticity, experience dependent
difluoromethylornithine
environmental complexity
environmental impoverishment
Positive palatability, 709
CGS 8216
chlordiazepoxide
direct enhancement
drug interactions
Ro 15-1788
Post-weaning exposure, 539
analgesia
locomotor activity
morphine
pre-weaning exposure
Prazosin, 791
alpha-adrenoceptors
clonidine
iminodipropionitrile
spasmodic syndrome, drug induced
Prefrontal cortex, 89
inferotemporal cortex
neuronal membrane proteins
visual discrimination
Pregnancy, 613
brain catecholamines
catecholamine turnover
dopamine
norepinephrine
seizure susceptibility
Pre-synaptic locus, 765
dopamine
drug interactions
locomotor activity
nucleus accumbens
opiates
Pre-weaning exposure, 539
analgesia
locomotor activity
morphine
post-weaning exposure
Prior drug experience, 141
adaptation
behavioral effects
environmental familiarity
delta-9-tetrahydrocannabinol
Prolactin, 619
atropine sulfate
cyclic AMP
footshock
immobilization
methylatropine nitrate
pituitary
stress
Propranolol, 229
aggression
brain transmitters
dose related effects
footshock aggression
Prostaglandin D_2, 543
cataleptic behavior
cholinergic system
dopaminergic system
serotonergic system
Psychostimulants, 841
behavioral effects
caffeine
cola seeds
drug comparisons
sub-chronic treatment
Psychomotor stimulants, 835
monkeys
norepinephrine
reinforcing effects
self-administration

Quantitative determination, 731
catecholaminergic agonists
catecholaminergic antagonists
drug comparisons
electrical brain stimulation
rewarding efficacy
^{3}H Quinuclidinyl benzilate, 671
cross tolerance, 173
in vivo administration, 671, 847
muscarinic receptors, 173
organophosphates, 173
phencyclidine, 671, 847
phencyclidine metabolites, 671, 847
strain differences, 173
tolerance, 173

Rabbits, 715
behavioral activation
benzazepine enantiomers
dopamine agonists
drug comparisons
EEG activation
SCH 23388
SCH 23390
Rabbits/rat comparisons
alpha$_2$ adrenoceptors, 437
caudate nucleus, 253
clonidine, 437
dopamine receptors, 253
jaw opening reflex, 437
nociception, 437
^{3}H-spirperone, 253
^{3}H-spiperone binding, 253
Radial maze performance, 23
drug interactions
ketamine
phencyclidine
righting reflex
Rate of responding, 191
chronic administration
monkeys
naloxone
shock titration
Rate suppressant effects, 199
drug discrimination
naloxone
β-phenylethylamine
stimulus properties
Rate, females, 393
lordosis
nicotine
nicotinic cholinergic transmission
ovariectomy
route of administration
sexual receptivity
Rats, males, 247
benzodiazepine receptor ligands
differential effects
drinking
isotonic saline consumption
water consumption
Rearing, 643
dopamine agonists
grooming
habenula nucleus
locomotor activity
Rearing, off-wall, 7
d-amphetamine
habituation
rearing, on-wall
Rearing-on-wall, 7
d-amphetamine
habituation
rearing, off-wall
Recovery, 813
acetylcholinesterase activity
choline aceyltransferase activity
diisopropylphosphofluoridate
muscarinic receptors
nicotinic receptors
sex differences
Reinforcement, 211
conditioned flavor aversion
conditioned place preference
neonates
odor
stimulant drugs
Reinforcing effects, 835
monkeys

norepinephrine
psychomotor stimulants
self-administration
Reinforcing properties, 719
discriminative properties
food deprivation
morphine
Repeated acquisition, 401
drug comparisons
ketamine
3,4-methylenedioxymetham-phetamine
monkeys
multiple schedule of performance
operant behavior, compex
phencyclidine
Reserpine
chronic administratioin, 203, 287
[^{3}H]DADLE binding, 203
depression, drug induced, 287
electroconvulsive shock treatment, 203
5-HT receptors, 287
6-hydroxydopamine, 203
5-hydroxytryptophan, 287
imipramine, 203
opioid δ receptor, 203
Respiration, 647
cats
flurazepam
pentobarbital
respiratory neurons
Respiratory neurons, 647
cats
flurazepam
pentobarbital
respiration
Restraint stress, 561
chlordiazepoxide
stress tolerance
ulcers
Retrieval, 183
memory
passive avoidance
vinpocetine
Reversible association, 475
atropine
BM123
drug interaction
N-methyl atropine
muscarinic receptor
Rewarding efficacy, 731
catecholaminergic agonists
catecholaminergic antagonists
drug comparisons
electrical brain stimulation
quantitative determination
Rhythmical slow activity, 357
behavioral effects
electrical activity
ethylcholine aziridinium ion
hippocampus
Righting reflex, 23
drug interactions
ketamine
phencyclidine
radial maze performance
Ritanserine, 333
anorexia, 5-HT induced
eating
5-hydroxytryptamine
Ro 5-4864, 381
caffeine
inbred strains
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate
picrotoxinin
seizure susceptibility
RO 15-1788
benzodiazepine antagonists, 631
CSG 8316, 709
chlordiazepoxide, 631, 709
direct enhancement, 709
drug interactions, 631, 709
exploration, 631
habituation, 631
locomotor activity, 631
positive palatibility, 709
Rotational behavior
d-amphetamine, 17, 527
directional behavior, 527
footshock, 17
perseveration, 527
rotational bias, 17
sex differences, 17
spontaneous alternation, 527
Rotational bias, 17
d-amphetamine
footshock
rotational behavior
sex differences
Route of administration
antidepressants, 35
benzodiazepine receptors, 35
cocaine, 375
drug comparisons, 573
[^{3}H]flunitrazepam binding sites, 35
hindlimb scratching, 327
locomotor activity, 573
lordosis, 393
muscarinic receptors, 327
neurokinins, 327
nicotine, 393
nicotinic cholinergic transmission, 393
norcocaine, 573
ovariectomy, 393
pilocarpine, 327
rats, females, 393
sexual receptivity, 393
RU 24213, 45
catalepsy
locomotor activity, backward walking
morphine
SKF 38393

Salbutamol, 421
behavioral effects
clonidine
hippocampus
intrahippocampal administration
yohimbine
Saline acceptance-rejection, 687
dopamine D-1 receptors
dopamine D-2 receptors
drinking
SCH 23390
sulpiride
water deprivation
Satiety, 515
feeding behavior
eating
meal patterns
naloxone
naltrexone
SCH 23388, 715
behavioral activation
benzazepine enantiomers
dopamine agonists
drug comparisons
EEG activation
rabbits
SCH 23390
SCH 23390
avoidance, 509
behavioral activation, 715
benzazepine enantiomers, 715
D1 receptors, 509
dopamine agonists, 715
dopamine D-1 receptors, 687
dopamine D-2 receptors, 687
drinking, 687
drug comparisons, 715
EEG activation, 715
operant responding, 509
rabbits, 715
saline acceptance-rejection, 687
SCH 23388, 715
sulpiride, 687
water deprivation, 687
Schedule-controlled responding
acetylcholinesterase inhibition, 119
behavioral-potency comparison, 425
formetanate, 119
N-methyl-1-(3,4-methylenedioxy-phenyl)-(2-aminopropane), 425
operant behavior, 119
phenylisopropylamines, 425
Schedule-induced polydipsia
acquisition and maintenance, 677
drinking, 677
midazolam, 797
naloxone, 677
physical dependence, 797
self-administration, oral, 797
Scopolamine, 195
locomotor activity
metabolic rate
Seasonal difference, 565
circannual rhythm
hibernation
opiates
squirrels
thermoregulation
Seizure susceptibility
brain catecholamines, 613
caffeine, 381
catecholamine turnover, 613
dopamine, 613
GABA antagonists, 71
inbred strains, 381
methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, 381
norepineprhine, 613
picrotoxinin, 381
pregnancy, 613
Ro 5-4864, 381
selective breeding, 71
strain differences, 71
Seizures, 159
amygdala
convulsions, drug induced
kindling
olfactory bulb
pentylenetetrazol
sensitization
Selective breeding, 71

GABA antagonists
seizure susceptibility
strain differences
Self-administration
benzodiazepines, 521
cocaine, 37
estrous cycle, 37
haloperidol, 37
monkeys, 521, 835
neuroleptic activity, 37
norepinephrine, 835
ovariectomy, 37
psychomotor stimulants, 835
reinforcing effects, 835
Self-administration, intravenous, 607
lesions, 5,7-dihydroxytryptamine
lesions, nucleus accumbens
serotonergic innervation
Self-administration, oral, 797
midazolam
physical dependence
scheduled-induced polydipsia
Self-injurious behavior, 187
antinociception
lesions, electrolytic
muscimol
stereotyped behavior
substantia nigra
superior colliculus
ventromedial thalamus
Sensitization, 159
amygdala
convulsions, drug induced
kindling
olfactory bulb
pentylenetetrazol
seizures
Serotonin, 821
d-amphetamine
brain monoamines
dopamine
dose differences
locomotor activity, nocturnal
long-lasting effects
stereotyped behavior
Serotonin efflux, 593
acute administration
chronic administration
clomipramine
differential effects
5-HT autoreceptors
nialamide
Serotoninergic system, 153
acute administration
analgesia
chronic administration
drug interaction
endogenous opioid system
beta-endorphin concentrations
Serotonergic innervation, 607
lesions, 5,7-dihydroxytryptamine
lesions, nucleus accumbens
self-administration, intravenous
Serotonergic system, 543
cataleptic behavior
cholinergic system
dopaminergic system
prostaglandin D_2
Sex differences
acetylcholinesterase activity, 813
d-amphetamine, 17
choline acetyltransferase activity, 813
diisopropylphosphofluoridate, 813
footshock, 17
muscarinic receptors, 813
nicotinic receptors, 813
recovery, 813
rotational behavior, 17
rotational bias, 17
Sexual receptivity, 393
lordosis
nicotine
nicotinic cholinergic transmission
ovariectomy
rats, females
route of administration
Sexual reward, 781
castration
conditioned place preference
estrous
mating behavior
naloxone
Sham feeding
benzodiazepine receptors, 497
CGS 8216, 497
DOPAC/DA ratios, 585
hypothalamus, 585
palatability, 497
sham feeding, 585
Shock titration, 191
chronic administration
monkeys
naloxone
rate of responding
SKF 38393, 45
catalepsy
locomotor activity, backward walking
morphine
RU 24213
Sleep-wake activity, 123
dopamine antagonists
dopamine autoreceptors
EEG slow wave activity
motor activity
Smooth pursuit eye movements, 103
ethanol
eye tracking
monkey/human comparisons
Sniffing, 299
apomorphine
electrophysiological correlates
stereotyped behavior
Social/agonistic interactions, 61
attack targets
defensive behavior
ethanol
group formation
offensive behavior
Spasmodic syndrome, drug induced, 791
alpha-adrenoceptors
clonidine
iminodipropionitrile
prazosin
Spinal analgesia, 445
cross tolerance
monoamine/opioid interactions
naloxone
tolerance
Spinal cord, 131
antinociception
continuous infusion
cross tolerance
^{3}H-Spiperone, 253
caudate nucleus
dopamine receptors
rabbit/rat comparisons
^{3}H-spiperone binding
^{3}H-Spiperone binding, 253
caudate nucleus
dopamine receptors
rabbit/rat comparisons
^{3}H-spiperone
^{3}H-Spiroperidol binding, 661
dopaminergic supersensitivity
haloperidol
locomotor activity
oral administration
stereotypy
Spleen, 851
catecholamine concentrations
experimental allergic encephalomyelitis
Spontaneous activity, 547
drug discrimination
methcathinone
stimulus generalization
Spontaneous alternation, 527
d-amphetamine
directional behavior
perseveration
rotational behavior
Spontaneous motor activity, 11
beta-adrenergic agonists
β1 receptors
β2 receptors
betaxolol
chronic administration
clenbuterol
IPS-339
Squirrels, 565
circannual rhythm
hibernation
opiates
seasonal difference
thermoregulation
Stereotyped behavior
d-amphetamine, 827
antinociception, 187
apomorphine, 299
brain monoamines, 827
dopamine, 827
dose differences, 827
electrophysiological correlates, 299
lesions, electrolytic, 187
locomotor activity, nocturnal, 827
long-lasting effects, 827
muscimol, 187
self-injurious behavior, 187
serotonin, 827
sniffing, 299
substantia nigra, 187
superior colliculus, 187
ventromedial thalamus, 187
Stereotypy, 661
dopaminergic supersensitivity
haloperidol
locomotor activity
oral administration
^{3}H-spiroperidol binding
Stimulant drugs, 211
conditioned flavor aversion
conditioned place preference
neonates
odor
reinforcement
Stimulus generalization, 547

drug discrimination
methcathinone
spontaneous activity
Stimulus properties, 199
drug discrimination
naloxone
β-phenylethylamine
rate suppressant effects
Strain differences
age differences, 83
aggression, shock-induced, 83
alcohol nonpreferring rats, 389
alcohol preferring rats, 389
cross-tolerance, 173
dose-response, 743
FK 33824, 743
forebrain, 389
GABA levels, brain, 83
GABA antagonists, 71
inbred mice, 83
linear running, 743
monoamine content, 389
muscarinic receptors, 173
opioids, 743
organophosphates, 173
QNB binding, 173
seizure susceptibility, 71
selective breeding, 71
tolerance, 173
wheel running activity, 743
Stress
atropine sulfate, 619
body weight gain, 293
chlorimipramine, 207
cyclic AMP, 619
desipramine, 207
footshock, 619
gastric secretion, 293
gastric ulceration, 293
hole board response, 207
immobilization, 619
mast cells, 293
methylatropine nitrate, 619
pituitary, 619
prolactin, 619
stress-induced behavior, 207
voluntary drug ingestion, 207
zinc deficiency, 293
Stress, chronic
concentration variations, 653
[^{3}H]cyclohexyladinosine binding, 821
footshock, 653
neuromodulator receptors, 821
neurotransmitter receptors, 821
norepinephrine, 653
Stress-induced behavior, 207
chlorimipramine
desipramine
hole board response
stress
voluntary drug ingestion
Stress, repeated, 259
α_2-adrenoceptors
β-adrenoceptors
chronic administration
immobilization stress
muscarinic cholinoceptors
nicotine
Stress tolerance, 561
chlordiazepoxide
restraint stress
ulcers
Subacute administration, 281
acute administration
diisopropylfluorophosphate
tolerance development
Sub-chronic treatment, 841
behavioral effects
caffeine
cola seeds
drug comparisons
psychostimulants
Substantia nigra, 187
antinociception
lesions, electrolytic
muscimol
self-injurious behavior
stereotyped behavior
superior colliculus
ventromedial thalamus
Subthalamic nucleus, 49
entopeduncular nucleus, 49
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventral globus pallidus
ventromedial thalamus
Sucrose
DOPAC/DA ratios, 585
hypothalamus, 585
isolation distress, 483
pain threshold, 483
sham feeding, 585
vocalizations, 483
Sulpiride, 687
dopamine D-1 receptors
dopamine D-2 receptors
drinking
saline acceptance-rejection
SCH 23390
water deprivation
Superior colliculus, 187
antinociception
lesions, electroytic
muscimol
self-injurious behavior
stereotyped behavior
substantia nigra
ventromedial thalamus
Superoxide dismutase, 235
alkali metals
in vitro
in vivo
lithium
mechanism of action
Sympathetic nervous system, 491
blood glucose responses
hyperglycemia, stress-induced
plasma insulin responses

Taste aversions, 553
cholinergic activity
hippocampus
odor aversions
Testes, 533
acute exposure
clonidine
hypothalamus
in vitro
in vivo
testosterone
Δ^9-tetrahydrocannabinol
Testosterone, 533
acute exposure
clonidine
hypothalamus
in vitro
in vivo
testes
Δ^9-tetrahydrocannabinol
Δ^9-Tetrahydrocannabinol
acute exposure, 533
adaptation, 141
behavioral effects, 141
clonidine, 533
environmental familiarity, 141
hypothalamus, 533
in vitro, 533
in vivo, 533
prior drug experience, 141
testes, 533
testosterone, 533
Thermoregulation
anterior hypothalamus/preoptic area, 373
cats, 373
circannual rhythm, 565
hibernation, 565
hypothermia, 373
α-noradrenergic receptors, 373
opiates, 565
seasonal difference, 565
squirrels, 565
Thiamine deficiency, 77
dopamine
drug interaction
muricide suppression
nonufensine
L-Threo-3,4-dihydroxyphenylserine, 407
benserazide
FLA-63
locomotor activity
nialamide
norepinephrine levels
Thyrotropin-releasing hormone, 639
cats
defecation
Time-dependent effects, 305
ACh formation
DOPAC/DA ratio
dose-dependent effects
locomotor activity
neurochemical actions
nicotine
Tolerance
acute administration, 29, 601
adenylate cyclase, 693
alcohol, 29, 693
analgesic effect, 57
behavioral impairment, 29
CGS 9896, 601
chronic administration, 601, 693
cross-tolerance, 173, 445
diazepam, 601
drug comparisons, 601
β-endorphin, 57
human studies, males, 29
in vitro, 693

learning, 29
liquid diet, 693
monoamine/opioid interactions, 445
muscarinic receptors, 173
naloxone, 445
organophosphates, 173
oxytocin, 57
QNB binding, 173
spinal analgesia, 445
strain differences, 173
withdrawal effects, 601
Tolerance development, 281
acute administration
diisopropylfluorophosphate
subacute administration
Toluene inhalation, 65
biphasic effects
dose-response
locomotor activity

Ulcers, 561
chlordiazepoxide
restraint stress
stress tolerance
Ultradian rhythm, 749
alcohol
alcohol preference
β-carbolines
drug comparisons
harmalan
Urinary output, 705
cyclazocine
diuresis
kappa agonist, partial
mu-antagonist
non-opioid agonist

Vagotomy, 757
adrenergic agonists
adrenergic antagonists
chickens
dose-response relationship
epinephrine
food intake
hepatic portal vein
Variable-interval hypothalamic self-stimulation, 49
entopeduncular nucleus
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
ventral globus pallidus
ventromedial thalamus
Vocalizations, 483
isolation distress
pain threshold
sucrose
Voluntary drug ingestion, 207
chlorimipramine
desipramine
hole board response
stress
stress-induced behavior
Vinpocetine, 183
memory
passive avoidance
retrieval
Visual discrimination, 89
inferotemporal cortex
neuronal membrane proteins
prefrontal cortex
Ventral globus pallidus, 49
entopeduncular nucleus
gabergic projections, pallidal
gabergic projections, striatal
locomotor activity
motivational effects
motor effects
muscimol
picrotoxin
subthalamic nucleus
variable-interval hypothalamic self-stimulation
ventromedial thalamus
Ventromedial thalamus
antinociception, 187
entopeduncular nucleus, 49
gabergic projections, pallidal, 49
gabergic projections, striatal, 49
lesions, electrolytic, 187
locomotor activity, 49
motivational effects, 49
motor effects, 49
muscimol, 49, 187
picrotoxin, 49
self-injurious behavior, 187
stereotyped behavior, 187
substantia nigra, 187
subthalamic nucleus, 49
superior colliculus, 187
variable-interval hypothalamic self-stimulation, 49
ventral globus pallidus, 49
Water consumption, 247
benzodiazepine receptor ligand:
differential effects
drinking
isotonic saline consumption
rats, males
Water deprivation
CGS 8216, 145
differential effects, 145
dopamine D-1 receptors, 687
dopamine D-2 receptors, 687
drinking, 145, 687
eating, 145
food deprivation, 145
naltrexone, 145
saline acceptance-rejection, 687
SCH 23390, 687
sulpiride, 687
Wheel running activity, 743
dose-response
FK 33824
linear running
opioids
strain differences
Withdrawal effects, 601
acute administration
CGS 9896
chronic administration
diazepam
drug comparisons
tolerance

Yawning
ACTH, 277, 503
adrenocorticotropic hormone, 5
apomorphine, 503
hypophysectomy, 277, 503
monosodium glutamate, 503
penile erection, 277, 503
Yohimbine, 421
behavioral effects
clonidine
hippocampus
intrahippocampal administratio
salbutamol
Zinc deficiency, 293
body weight gain
gastric secretion
gastric ulceration
mast cells
stress

AUTHOR INDEX

Abe, Y., 77
Ahluwalia, P., 653
Alföldi, P., 123
Al-Khatib, Iz. M. H., 351
Alkondon, M., 229
Alleva, E., 539
Alpern, H. P., 71
Amalric, M., 765
Anderson, S. M., 829
Ando, K., 103
Andrews, J. S., 167
Anisman, H., 653
Antkiewicz-Michaluk, L., 203
Aprison, M. H., 287
Argiolas, A., 503
Axon, D. I. R., 45

Babbini, M., 719
Bacchi, A., 719
Baker, R. C., 693
Balansard, G., 841
Baran, L., 35
Barber, D. J., 145
Bartoletti, M., 719
Baum, M. J., 781
Baumeister, A. A., 187
Beleslin, D. B., 373, 639
Bermúdez-Rattoni, F., 553
Bernet, F., 421
Berridge, K. C., 709
Blanchard, D. C., 61
Blanchard, R. J., 61
Blass, E., 483
Blundell, J. E., 515
Boast, C. A., 601
Boggan, W. O., 671, 847
Booth, R. A., 475
Boudinot, E., 647
Bourbonais, K. A., 585
Bowers, W., 653
Braun, T., 791
Brini, A., 153
Broekkamp, C. L. E., 771
Broitman, S. T., 207
Brufani, M., 625
Brugge, K. L., 287
Büchau, C., 749
Bushnell, P. J., 195

Cabib, S., 83
Cadet, J. L., 791
Caffry, E. W., 321
Calcagnetti, D. J., 743
Camp, D. M., 821
Caporali, M. G., 715
Carlson, J. N., 17
Carlsson, A., 123
Carney, J. M., 381
Cash, R., 11
Castellano, C., 625
Cervenko, F., 445
Cervenko, F. W., 131
Chai, C. Y., 427
Champagnat, J., 647
Chávez, A. F., 553
Cho, C. H., 293
Ciesielski, L., 83
Clemens, L. G., 393
Clement, J., 83
Clopton, J. K., 223
Co, C., 607
Coburn, K. L., 553
Cochrane, C., 491
Collins, A. C., 173, 813
Collu, M., 277
Cooper, S. J., 145, 247, 497, 687
Curtin, J. C., 223
Curtis, A. L., 437

Dalterio, S., 533
Dalton, J. C. H., 37
Danti, S., 11
Darwish, M., 271
Denavit-Saubie, M, 647
DeNoble, V. J., 183
De Paolo, L., 533
Dietrich, R. A., 693
Dworkin, S. I., 607
Dykstra, L. A., 191

Eggleston, T., 619
Elliott, P. J., 573
Ellison, G. D., 1
Emm, T., 313
Estall, L. B., 247
Eterović, V. A., 341
Evans, J. A. C., 643

Falk, J. L., 797
Faught, K., 847
Feinglos, M. N., 491
Feldon, J., 241
Ferchmin, P. A., 341
Fernández, J., 553
Fernando, J. C. R., 281
File, S. E., 631
Fitzgerald, E., 483
Flannelly, K., 61
Fletcher, G. H., 45
Flux, M., 381
Flynn, J. J., 743
Fong, L. Y. Y., 293
Forbes, J. M., 757
Fóscolo, M. R., 207
Foutz, A. S., 647
Frances, H., 11
Fratta, W., 277, 503
Freed, W. J., 791
Freeman, G. B., 305
Fregley, M. J., 431
Frey, J. M., 661
Freyd, G., 731
Friedman, E., 635
Frye, G. D., 187
Fujiwara, M., 351, 543

Gaiardi, M., 719
Galen, D. M., 1
Gallistel, C. R., 731
Garcia, J., 553
Gerhardt, S. C., 601
Gertner, S. B., 683
Gessa, G. L., 277, 503
Gianutsos, G., 635
Gibson, G. E., 305
Gilbert, D. B., 687
Giordano, M., 7
Glennon, R. A., 425, 547
Glick, S. D., 17
Goeders, N. E., 607
Gonsalves, S. F., 647
Goode, T. L., 327
Gordon, J. H., 223
Goudie, A. J., 199
Gramlich, C. A., 159
Griffiths, R. R., 801
Gubellini, C., 719

Jadot, G., 841
Jenden, D. J., 475
Jerome, C., 585
Jhamandas, K., 445
Jhanwar-Uniyal, M., 271
Johanson, C. E., 103, 521
Johansson, A. M., 123
Jones, B., 141
Jørgensen, O. S., 89
Jourdan, M. L., 565
Jovanović-Micić, D., 639

Hagan, J. J., 771
Hajós, M., 123
Han, P. C., 813
Hanin, I., 357
Harder, D. R., 851
Haubenreisser, T., 29
Heath, R. W., 145
Henke, P. G., 561
Herberg, L. J., 49
Hernandez, L. L., 253
Hinds, P. A., 17
Hingtgen, J. N., 287
Hinman, D. J., 65
Ho, B. T., 365
Ho, I. K., 281
Hodge, W., 141
Holman, E. W., 211
Holtzman, S. G., 167
Hori, K., 61
Hoskins, B., 281
Howes, G. A., 757
Huffman, R. D., 661

Ingram, D. K., 95
Irwin, J., 653
Iwasaki, K., 351

Kalin, N. H., 699
Kalix, P., 547
Kamiya, H., 543
Kant, G. J., 619, 829
Karai, N., 407
Kataoka, Y., 351, 725
Kato, T., 407
Katsube, J., 407
Katsuyama, M., 407
Katz, Y., 241
Kehoe, P., 483
Keller, E. A., 417
Kigoshi, S., 259
Kirkham, T. C., 145, 497, 515
Kisara, K., 77
Kissileff, H. R., 321
Kokkinidis, L., 527
Koller, W. C., 223
Konkol, R. J., 851
Koob, G. F., 765
Kostowski, W., 217
Kovács, G. L., 57
Kuhn, C. M., 491

Landman-Roberts, L., 619
Laviola, G., 539
Leander, J. D., 705
Lee, E. H. Y., 427
Lee, T. F., 565
Leibowitz, S. F., 271
Leo, G. L., 851
Lesko, L., 313
Leu, J. R., 829
Leventer, S. M., 557
Levin, B. E., 271
Levin, E. D., 1
Li, T.-K., 389
Lim, D.-K., 281
Lister, R. G., 631
Little, P. J., 425
London, E. D., 95
Loomis, C. W., 131, 445
Lumeng, L., 389

McBride, W. J., 389
McCann, D. J., 23
McIntyre, T. D., 71
McMahon, T. F., 313

Ma, P. C. C., 293
MacPhail, R. C., 119
Maillard, C., 841
Mandel, P., 83
Mantegazza, P., 153
Margules, D. L., 743
Marini, S., 333
Marona-Lewicka, D., 203
Marta, M., 625
Martin, P., 141
Marwah, J., 437, 453
Massi, M., 333
Massotti, M., 715
Mastropaolo, J., 401
Mauri, A., 503
Medhurst, L. J., 173
Melis, M. R., 503
Meyerhoff, J. L., 619
Michaluk, J., 203
Middaugh, L. D., 671, 847
Miller, R. L., 781
Milne, B., 131, 445
Mogensen, J., 89
Molina, V. A., 417
Moore, L. L., 187
Morgan, W. W., 661
Morin-Surun, M.-P., 647
Mos, J., 577
Moser, V. C., 119
Muramatsu, I., 259
Murphy, J. M., 389
Myers, R. D., 373

Naiman, N., 547
Nakamura, M., 407
Nemeroff, C. B., 573

Obál, F., Jr., 123

Offord, S. J., 593
Ogle, C. W., 293
Oliverio, A., 625
Oliveto, A. H., 191
Olivier, B., 577
O'Neill, K. A., 683
Ongini, E., 715
Ono, N., 543
Orsingher, O. A., 417
Overstreet, D. H., 475

Pagella, P. G., 625
Panerai, A. E., 153
Pavone, F., 625
Peluso, J., 533
Pitts, D. K., 453
Pomponi, M., 625
Pope, C. N., 365
Powell, D. A., 253
Przegaliński, E., 35
Pucilowski, O., 217
Puglisi-Allegra, S., 83

Rabin, R. A., 23, 693
Raffa, R. B., 327
Raisman, R., 11
Ray, A., 229
Rennert, O. M., 381
Renwart, N., 11
Rezvani, A. H., 373
Riley, A. L., 677
Roache, J. D., 801
Roberts, D. C. S., 37
Robinson, T. E., 821
Rodríguez Echandía, E. L., 207
Roerig, D. L., 851
Rokosz-Pelc, A., 35, 203
Rommelspacher, H., 749
Rosecrans, J. A., 425
Rosen, G. M., 573
Royal, M., 141
Rubicsek, G., 123
Rugarli, P. L., 625
Russell, K. H., 7
Russell, R. W., 475

Sacerdote, P., 153
Sagratella, S., 715
Saito, R., 543
Sakurai, Y., 725
Samardzić, R., 639
Sanberg, P. R., 7
Sanger, D. J., 509
Sawynok, J., 463
Schechter, M. D., 413
Schultz, C. E., 709
Schuster, C. R., 103
Scott, R. W., 327
Scotto, G., 841
Seale, T. W., 381
Sen, P., 229
Serra, G., 277
Sherman, J. E., 699
Sherman, K. A., 305
Shukla, G. S., 235
Shultz, K., 607
Simansky, K. J., 585
Simler, S., 83
Simon, P., 11
Skolnick, P., 381
Smith, C. A., 211
Smith, G. P., 585
Smith, J. E., 607
Smolen, A., 173, 613, 813
Smolen, T. N., 173, 613, 813
Spangler, E. L., 95
Starr, M. S., 45
Steger, R., 533
Stewart, D. J., 357
Stringer, A. J., 847
Stripling, J. S., 159
Surwit, R. S., 491
Svensson, K., 123
Swerdlow, N. R., 765
Szechtman, H., 299

Tadano, T., 77
Tang, M., 797
Tang, Y. P., 427
Tani, Y., 725
Telegdy, G., 57
Terzić, B., 639
Thompson, D. M., 401
Thornton, E. W., 643
Thornton, J. C., 321
Ticku, M. K., 661
Tonnaer, J. A. D. M., 771
Treit, D., 709
Trzaskowska, E., 217
Tsai, M. J., 427

Ueki, S., 111, 351, 725
Ushio, M., 725

Valzelli, L., 217
van de Kamp, J. L., 613
van der Laan, J. W., 265
Vanderwolf, C. H., 299, 357
van Oorschot, R., 577
Verleye, M., 421
Vetulani, J., 35, 203
Vickers, G. J., 37
Vion-Dury, J., 841
Vogel-Sprott, M., 29

Walovitch, R. C., 95
Wang, L. C. H., 565
Warwick, R. O., Jr., 593
Weaver, D. R., 393
Weiner, I., 241
Weiner, M., 313
Weiss, J., 749
Wetherington, C. L., 677
Wesselmann, U., 851
Wickens, A., 643
Williams, S. F., 49
Winsauer, P. J., 401
Winter, J. C., 23
Woolverton, W. L., 835
Wright, A. A., 365

Yamamoto, T., 111
Yamanaka, K., 259
Yamashita, K., 725
Yonezawa, A., 77
Yousif, M., 425, 547

Zacharko, R. M., 653